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Atherosclerosis is responsible for up to 29% of all deaths worldwide, making 
it a major cause of death especially in developed countries. Serum Amyloid A 
(SAA), a major acute phase protein, is found to be elevated in atherosclerotic 
patients. Other than just being a marker of atherosclerosis, SAA is suspected 
to play a direct role in coronary artery disease (CAD). However, the 
mechanisms through which SAA contributes to atherosclerosis are still largely 
unknown. Inflammation is known to play a role in all stages of atherosclerosis 
while apoptosis is now seen as a key event in atherosclerosis due to its ability 
to affect plaque stability. Given the role of inflammation and apoptosis in 
atherosclerosis, the objective of this study is to determine whether SAA could 
contribute to atherosclerosis through these pathways.  
 
Methods and Results 
Quantitative real-time PCR carried out after RAW264.7 macrophages were 
exposed to various concentrations of SAA showed that SAA was able to 
induce the expressions of ICAM-1, MCP-1, MMP-9 and TF in RAW264.7. 
These targets are known to play important roles in the initiation and 
progression of atherosclerosis. Inhibition of NFκB using Bay11-7082 before 
cells were exposed to SAA significantly suppressed the induction of these 
targets following SAA treatment. Through MTT assay, the ability of SAA to 
IX 
 
reduce cell viability was observed. Regulation of apoptotic targets - Fas and 
Bcl-2 were detected after cells were exposed to SAA for various time-
durations. Western blot carried out on cells treated with SAA for various time-
durations also showed evidences of apoptosis taking place following SAA 
treatment with the detection of caspase 3 activation and PARP cleavage. 
Although NFκB is usually known for its cell survival effects, inhibition of 
NFκB before cells were exposed to SAA eliminated the apoptotic effects of 
SAA.    
 
Conclusion 
Results obtained from this project suggest that SAA is able to contribute to 
atherosclerosis through both the inflammatory and apoptotic pathway, with 
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Atherosclerosis, a main cause of coronary artery disease (CAD), is a 
progressive disease caused by the deposition of lipids and inflammatory cells 
within arterial walls (Halvorsen et al., 2008; Libby, 2002; Lusis 2000; Ross, 
1999). CAD is the most common cause of death in developed countries 
(Madan et al., 2008; Ross, 1999) and risk factors of CAD include diet, 
smoking status, physical activity, diabetes, hypertension and genetics 
(Halvorsen et al., 2008; Hegyi et al., 2001). Atherosclerosis, being the main 
cause of CAD, is responsible for up to 75% of CAD related deaths (Yang et al., 
2007). In fact, it is estimated that atherosclerosis is responsible for about 19 
million deaths each year (Halvorsen et al., 2008; Myerburg, 1997). 
Furthermore, about 29% of all deaths worldwide are caused by atherosclerosis. 
With the increasing prevalence of CAD in both developed and developing 
countries, atherosclerosis is expected to be the main cause of death globally in 
the next twenty years (Ramsey et al., 2010).  
 
1.1.1. Disease progression 
Before 1980s, atherosclerosis was thought to be a passive disease caused by 
the accumulation of cholesterol in blood vessels (Ramsey et al., 2010; Libby, 
2002). Inflammation, a defense mechanism of the body, has been linked to 
atherosclerosis since 1980s and today, we have come to know the prominent 
role inflammation has in contributing to the initiation and progression of the 
disease (Dabek et al., 2010; Cullen et al., 1999).  
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In recent years, endothelial dysfunction is believed to be the initial cause of 
atherosclerosis. Causes of endothelial dysfunction include modified Low 
Density Lipoprotein (LDL), cigarette smoke derived free radicals and diseases 
such as diabetes and hypertension (Ross, 1999).  
Following the initiation of atherosclerosis, usually caused by endothelial 
dysfunction, vascular endothelial cell increases the expression of leukocyte 
adhesion molecules on its surface (Libby et al., 2010; Boyle, 2005; Ross, 
1999). The up-regulation of adhesion molecules such as intercellular adhesion 
molecule-1 (ICAM-1) increases the interaction between the endothelium and 
circulating leukocytes such as monocytes (Shimizu et al., 2006). With the help 
of chemokines such as monocyte chemoattractant protein-1 (MCP-1), 
monocytes soon gain entry into the intima through endothelial cell junctions 
via diapedesis (Libby et al., 2010; Ramsey et al., 2010; Libby, 2002).  
In the intima, monocytes differentiate into macrophages which internalize 
modified lipoproteins via scavenger receptors such as CD36 and oxidized 
LDL receptor-1 (LOX1), forming foam cells which are hallmark of 
atherosclerotic lesions in early stages (Libby et al., 2010; Shibata and Glass, 
2010; Madan et al., 2008; Mercer et al., 2007). Inflammatory response of the 
immune system following endothelial dysfunction results in the buildup of 
lesion at the localized site. Fatty streaks which consist of macrophages and T-
lymphocytes are classified as lesion in its earliest form. These lesions can be 
detected as early as in young children or even in infants (Palinski and Napoli, 
2002; Napoli et al., 1997).  
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Within the intima, activated macrophages also release chemokines, cytokines 
and growth factors which result in the multiplication of both vascular and 
leukocyte cells in the lesion. Macrophages also undergo proliferation within 
the intima, secreting Matrix Metalloproteinases (MMP) and Tissue Factor (TF) 
(Libby, 2002). Such continual inflammatory response results in further buildup 
of the lesion into intermediate and subsequently, advanced lesion. 
The lesion may eventually intrude into the arterial lumen, resulting in blood 
flow alteration (Ross, 1999). As the lesion continues to grow, cell death 
occurring at the centre of the core eventually causes plaque destabilization 
(Stoneman and Bennett, 2004). The uneven thinning or erosion of the fibrous 
cap at the shoulder of the lesion may promote plaque rupture resulting in 
thrombus formation following contact of plaque contents with surrounding 
blood clotting factors (Stoneman and Bennett, 2004). A fatal consequence of 
myocardial infarction may then occur in the event of thrombosis (Kume et al., 
2009; Seli et al., 2006).  
 
 
1.2. Macrophages  
Monocytes derived macrophages which form part of the human innate 
immunity are able to recognize foreign particles and modified LDL. Under 
normal inflammatory conditions, the toll-like receptors (TLR) and scavenger 
receptors of activated macrophages are induced, allowing for the elimination 
of harmful particles via phagocytosis (Wilson, 2010; Xu et al., 2001). In this 
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way, homeostasis is restored with inflammatory reaction being self-limiting 
(Wilson, 2010). 
 
1.2.1. Macrophages in atherosclerosis 
As the first inflammatory cell to be identified in atherosclerotic plaques, 
macrophages have been associated with atherosclerosis since the 1960s 
(Wilson, 2010). Over the years, macrophages are found to play a prominent 
role in all stages of atherosclerosis (Wilson, 2010). Macrophages, when 
induced by stimuli such as lipopolysaccharide (LPS), release pro-
inflammatory mediators which play a role in both i) initiation and ii) 
progression of atherosclerosis (Halvorsen et al., 2008). The importance of 
macrophages in contributing to atherosclerosis can be seen from the reduction 
in lesion observed in studies using mice with depleted monocytes or 
monocytes blocked from entering into lesions (Smith et al., 1995). 
i) Involvement of macrophages in initiation of atherosclerosis 
The role of macrophages in atherosclerosis begins from the initiation stage. 
Following endothelial dysfunction, monocytes are recruited into the intima 
with the help of various adhesion molecules and chemoattractants.  
Within the intima, monocytes differentiate to form macrophages, acquiring 
scavenger receptors which allow them to phagocytose modified lipoprotein, 
forming foam cells. These foam cells are able to release chemokines, 
cytokines, growth factors and proteases which sustain the inflammatory 
response through the migration and proliferation of various vascular cells 
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(Wilson, 2010; Seli et al., 2006). The continual secretion of inflammatory 
factors by macrophages therefore, results in the build up of atherosclerotic 
plaques. 
ii) Involvement of macrophages in progression of atherosclerosis 
Plaque progression involves plaque instability and the eventual rupture of 
plaque. Over the years, an association between macrophages and plaque 
vulnerability has been observed. In fact, there is a correlation between the 
number of macrophages present and the vulnerability of a plaque (Glass and 
Witztum, 2001). Macrophages, the most prominent cell type in atherosclerotic 
plaques (Tabas, 2004), showed more extensive infiltration in vulnerable 
compared to stable plaques (Laufer et al., 2009). Also, plaques with necrotic 
core filled with dead macrophages are classified as a prominent feature of 
vulnerable plaques (Tabas, 2004; Virmani et al., 2002).  
Macrophages have also been associated with plaque rupture as sites with high 
macrophage ratio are more likely to undergo rupture (Van der Wal et al., 
1994). Indeed, macrophages are found to be the majority cell type at rupture 
sites (Kolodgie et al., 2000). The detection of more macrophages in fibrous 
caps of ruptured plaque versus those of non-ruptured plaque also gives an 







1.3. Serum Amyloid A (SAA) 
SAA is a 12.5kDa acute phase reactant which plays a role in the acute phase 
response. The host immediate response following an injury is known as the 
acute phase response (Uhlar and Whitehead, 1999). It is a systemic response 
that plays an important role in the host defense system, through the 
minimization of tissue damage and promotion of healing (Baranova et al., 
2010; Sandri et al., 2008). In the event of a tissue injury, the acute phase 
response initiates the activation of a cascade, resulting in the synthesis and 
release of acute phase proteins from the liver (Baranova et al., 2010). Well-
established acute phase reactants include SAA and C-Reactive Protein (CRP).  
 
1.3.1. SAA synthesis 
SAA is mainly synthesized in the liver as like other acute phase reactants 
(Filep and Kebir, 2008; Urieli-Shoval et al., 2000). Synthesis of SAA by 
hepatocytes can be potently induced by various stimuli including Interleukin 
(IL)-6, Tumor Necrosis Factor α (TNFα) and IL-1B (Carty et al., 2009; Filep 
and Kebir, 2008). However, studies have also found the production of SAA at 
extrahepatic sites such as adipocytes and intestinal epithelial cells (Urieli-
Shoval et al., 1998). Interestingly, SAA is also found to be synthesized and 
secreted by the various cell types which make up atherosclerotic lesions. 
These cell types include the endothelial cells, smooth muscle cells, monocytes 
and macrophages (Baranova et al., 2010; Song et al., 2009; Sandri et al., 2008; 
Hatanaka et al., 2003; He et al., 2003; Urieli-Shoval et al., 2000).  
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As a major acute phase reactant, SAA is found at low levels in healthy 
individuals but its expression can markedly increase by up to 1000 fold of 
resting level, to 1mg/ml, within 24 – 36 h following an insult such as an 
infection, inflammation or a trauma (Malle and De Beer, 1996). This level will 
start to decline after 4-5 days, with the normal baseline level being recovered 
by 10-14 days (Gabay and Kushner, 1999). During an acute phase response, 
SAA makes up to 2.5% of the total protein synthesized by the liver, suggesting 
the importance of SAA in the host protective biological system (Uhlar and 
Whitehead, 1999; Malle and De Beer, 1996). Given its rapid response and 
wide dynamic range, SAA has been proposed to be used as an indicator of 
certain diseases which will be further discussed later (Cunnane et al., 2000). It 
is also seen as a more sensitive marker of inflammation compared to CRP 
(Carty et al., 2009; Malle et al., 2009).  
 
1.3.2. SAA conservation 
The SAA gene is highly conserved across multiple species, including human, 
mouse, rabbit, dog, sheep and horse through evolution (Uhlar and Whitehead, 
1999). As a multigene, SAA is made up of four genes located on four different 
loci on chromosome 11 in humans (Urieli-Shoval et al., 2000). In mice, these 
genes are located on chromosome 7 (Filep and Kebir, 2008). Of the four genes, 
SAA1 and SAA2 are collectively classified as the acute phase proteins, known 
as A-SAA (Filep and Kebir, 2008; Marsche et al., 2007; Jensen and Whitehead, 
1998), with SAA1 being the more dominant type (Malle et al., 2009; Sipe, 
1999). SAA4 is constitutively expressed under normal conditions and thus, 
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known as C-SAA; while SAA3 is found to be secreted and expressed by 
adipocytes (Fasshauer et al., 2004). This high degree of homology amongst the 
different species through evolution suggests functional importance of SAA 
(Malle et al., 2009). 
 
1.3.3. Roles of SAA 
As an evolutionarily conserved protein of more than 400 million years, SAA is 
seen as a protein with indispensible function (Urieli-Shoval et al., 2000). In 
addition to its role as an acute phase protein as mentioned earlier, SAA is also 
involved in various physiological processes (Lee et al., 2006). 
SAA itself contains binding sites for several proteins including those for high 
density lipoproteins (HDL), laminin and fibronectin (Urieli-Shoval et al., 
2000). With the detection of adhesion motifs such as laminin and fibronectin 
on SAA itself, SAA has been associated with functions such as cell adhesion, 
aggregation and proliferation (Urieli-Shoval et al., 2000).  
SAA has a high affinity for HDL and is thus, also known to play a role in 
cholesterol transport and lipid metabolism (Urieli-Shoval et al., 2000). With 
their high affinity, SAA is mainly associated with HDL in the circulation 
(Zhao et al., 2010; Stonik et al., 2004) although findings of association 
between SAA and oxidized LDL (ox-LDL) to form SAA-LDL complex have 
also been reported (Kotani et al., 2009; Ogasawara et al., 2004). At elevated 
level, SAA is able to replace apoA-I in HDL, taking over as the predominant 
apolipoprotein of HDL (Coetzee et al., 1986). SAA-enriched HDL is larger in 
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both size and density (Ashby et al., 2001). Effects of SAA-enriched HDL on 
cholesterol transport and lipid metabolism would be further discussed later. 
At elevated level, once HDL is saturated, SAA is also able to exist in the 
circulation as a lipid free-SAA (Malle and De Beer, 1996). SAA, when 
independent of lipoprotein, has a pro-inflammatory effect. The detection of 
lipoprotein free SAA at inflamed sites suggests possible role of SAA in 
contributing to inflammation (Meek et al., 1994). SAA is found to be able to 
activate transcription factor Nuclear Factor kappa B (NFκB) and thus, 
regulates the expression of NFκB target genes (Filep and Kebir, 2008; Mullan 
et al., 2006). SAA could also induce the secretion of pro-inflammatory 
cytokines such as TNFα and IL-IB in human neutrophils and monocytes (Lee 
et al., 2006). With its pro-inflammatory property, the presence of both SAA 
and pro-inflammatory molecules would result in a vicious positive cycle of 
inflammation, resulting in chronic inflammation (Malle et al., 2009).  
 
1.3.4.  SAA receptors 
To date, many receptors of SAA have been identified. Formyl peptide receptor 
like-1 (FPRL1), a G-protein coupled receptor with 7 transmembrane domain, 
is mainly involved in the chemoattractant property of SAA (Baranova et al., 
2010; Malle et al., 2009; Lee et al., 2006) while scavenger receptor B-I (SR-BI) 
is required for the cholesterol efflux effect of the SAA-HDL complex 
(Wadsack et al., 2003). Toll like receptor 2 (TLR2) is found to be responsible 
for SAA-mediated inflammatory cytokine stimulation (Cheng et al., 2008), 
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while TLR4 is associated with SAA-induced nitric oxide radical production 
(Sandri et al., 2008).  
 
1.3.5. Link to diseases 
As its name suggest, SAA is the serum precursor of amyloid A, whose 
deposition, due to persistently high SAA level, results in amyloidosis (Filep 
and Kebir, 2008; Urieli-Shoval et al., 2000). These depositions, when 
accumulate in major organs, could potentially result in fatality (Gilmore et al., 
2001; Jensen and Whitehead, 1998).  
SAA is seen as an inflammatory biomarker as its level increases by up to 1000 
fold following inflammation (Malle and De Beer, 1996). As expected, an 
association between serum SAA level and acute inflammation is observed 
(Filep and Kebir, 2008). SAA is therefore, viewed as a valuable indicator for 
chronic inflammatory diseases diagnosis (Lee et al., 2006). However, instead 
of being a responder, SAA is found to be an active participant in inflammation 
as it is able to modulate pro-inflammatory response (Mullan et al., 2006; 
Urieli-Shoval et al., 2000). 
As SAA is associated with inflammation, SAA is found to be highly expressed 
in patients of chronic inflammatory conditions such as rheumatoid arthritis, 
Alzheimer’s disease, neoplasia and atherosclerosis (Lee et al., 2006). SAA is 
also found at elevated levels in various cancer variants (Lee et al., 2006) and 
has been considered as a tumor progression marker (Vlasova et al., 2006).  
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SAA is found to be elevated in conditions such as diabetes, obesity and 
metabolic syndrome which are known risk factors of atherosclerosis 
(Baranova et al., 2010; Filep and Kebir, 2008). Compared to healthy 
individuals, diabetic patients have a higher level of SAA. Conversely, 
individuals with higher SAA level have a higher chance of becoming diabetic 
(Zhao et al., 2010; Herder et al., 2006). Rosiglitazone and thiazolidinediones 
which are used for the treatment of diabetes are able to reduce SAA level 
(Zhao et al., 2010; Filep and Kebir, 2008; Hetzel et al., 2005). For the 
association of SAA with obesity, a correlation between SAA level and Body 
Mass Index (BMI) of individuals is detected. A loss in weight would similarly, 
register reduced SAA level (Zhao et al., 2010). Recently, a correlation was 
found between SAA-LDL concentration in circulation and metabolic 
syndrome (Kotani et al., 2009). There were also evidences suggestive of SAA-
LDL complex playing a role in atherosclerosis (Ogasawara et al., 2004).  
The presence of SAA in these diseases suggests the likelihood of SAA in 
contributing to inflammation itself (He et al., 2003). With higher inducibility 
and sensitivity than CRP, SAA is also seen as a better marker for the detection 
of inflammatory diseases (Johnson et al., 2004). 
1.3.5.1.  Link to Atherosclerosis 
As previously mentioned, atherosclerotic lesion is one of the sites that 
expresses SAA, as evidenced by the detection of SAA mRNA in various types 
of cells found within atherosclerotic lesions and foam cells (Meek et al., 1994). 
SAA protein is also detected in atherosclerotic plaques of human and vascular 
smooth muscle cells of rabbits (Kumon et al., 1997; Yamada et al., 1996).  
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Similar to other inflammatory conditions, SAA is found at a higher level in 
atherosclerotic patients compared to healthy individuals (Ridker et al., 2000). 
Over the years, studies have found a link between elevated level of SAA and 
worsening coronary conditions, including unstable angina and acute 
myocardial infarction (Liuzzo et al., 1994). Further elevated SAA level is 
detected at sites of plaque rupture (Liuzzo et al., 1994). Conversely, a 
reduction in SAA level is thought to beneficial for atherosclerotic patients 
(Filep and Kebir, 2008). There is therefore, a correlation between the level of 
SAA and risk of cardiovascular disease (Jousilahti et al., 2001).  
In fact, the potential of SAA to be used as a marker to predict cardiovascular 
events has been proposed (Johnson et al., 2004). The Inflammation and 
Carotid Artery – Risk for Atherosclerosis Study (ICARAS) done by 
Schillinger and team showed the feasibility of using SAA to track 
atherosclerotic progression (Schillinger et al., 2005). Another study known as 
the Women’s Ischemia Syndrome Evaluation (WISE) study carried out by 
Johnson and his team further demonstrated SAA’s ability to predict 3-year 
cardiovascular events in females who were suspected of ischemia (Johnson et 
al., 2004). The team also observed a strong association between SAA level and 
cardiovascular complications in the future (Johnson et al., 2004). Studies on 
the role of SAA-LDL in atherosclerosis also found a correlation between 
SAA-LDL complex level and risk of future cardiac event in patients of stable 
CAD (Ogasawara et al., 2004). Compared to other inflammatory molecules, 
SAA is seen as the more sensitive predictor of cardiovascular disease (Uurtuya 
et al., 2009).  
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Other than just being a marker, SAA is suspected to play a direct role in CAD 
through the amplification or mediation of atherosclerosis (Song et al., 2009).  
i) Lipid independent SAA 
As mentioned previously, lipid independent SAA has a proinflammatory effect 
(Malle and De Beer, 1996). The role of inflammation in various stages of 
atherosclerosis has been well-established (Hansson, 2005).  
SAA is found to have a chemotactic effect on inflammatory cells such as 
monocytes, promoting the migration of these cells to the injured site, an early 
step of atherosclerosis (Song et al., 2009). Chemotactic effect of SAA on 
neutrophils has also been reported (Su et al., 1999). There were also reports on 
the ability of SAA to stimulate inflammatory cytokine and MMPs production 
in monocytes (Baranova et al., 2010; Zhao et al., 2009). The production of 
MMPs could result in plaque instability following extracellular matrix 
degradation (Filep and Kebir, 2008).  
In human endothelial cells, Zhao and her team found the ability of SAA to 
stimulate both TF expression and activity, which promotes blood coagulation 
and subsequently, thrombogenesis (Zhao et al., 2007). A correlation between 
SAA and TF level was also detected in patients (Song et al., 2009). Cellular 
adhesion molecules (CAMs) which plays an important role in atherosclerosis 
initiation was also found to be significantly induced by SAA in endothelial 
cells (Mullan et al., 2006).  
SAA is able to reciprocally regulate TNFα in neutrophils and monocytes 
(Hatanaka  et al., 2004; Lee et al., 2005). TNFα, being a mediator of 
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inflammation, would contribute to the vicious cycle of inflammatory response, 
leading to the progression of atherosclerosis (Song et al., 2009).  
ii) Lipid bound SAA 
At elevated level, SAA is able to replace apoA-I in HDL (Coetzee et al., 1986). 
Due to its association with HDL and the findings of its expression in 
atherosclerotic plaques, SAA has been hypothesized to play a role in 
atherosclerosis (Kisilevsky and Tam, 2002). 
HDL plays an important role in reverse cholesterol transport, which is the 
transport of excess cholesterol from peripheral sites to the liver for degradation, 
preventing atherosclerosis. At elevated SAA level where apoA-I in HDL gets 
displaced by SAA, there were reports of a reduction in the ability of HDL to 
carry out cholesterol efflux, affecting reverse cholesterol transport (Marsche et 
al., 2007; Blanka et al., 1995). This finding is consistent with the observation 
of a correlation between SAA level and atherosclerotic progression. 
Conversely, some studies have reported anti-atherogenic properties of SAA. 
Studies have shown that SAA could promote efflux of cholesterol via the 
ATP-binding cassette transporter A1 (ABCA1) receptor, facilitating lipid 
removal and preventing lipid accumulation (Stonik et al., 2004). SAA is also 
found to be able to facilitate cholesterol efflux independent of ABCA1 
receptor due to its ability to bind to both HDL and cells directly (Stonik et al., 
2004). SAA could bind directly to cholesterol, modulating its metabolism 





1.4. Nuclear factor kappa B (NFκB) 
First discovered in 1986 by Sen and Baltimore, nuclear factor kappa-light-
chain – enhancer of activated B cells (NFκB) is a nuclear transcription factor 
that is responsible for the regulation of a wide range of genes, including genes 
that are involved in immune response and inflammation; genes encoding for 
growth factors and cytokines; and also genes relating to apoptosis (Dabek et 
al., 2010). NFκB is thus, known for its roles in the immune system, 
inflammation, cell growth, angiogenesis, metastasis, cell survival and 
apoptosis (Chopra et al., 2008; Kucharczak et al., 2003).  
 
1.4.1. The NFκB family 
NFκB is an evolutionarily conserved family consisting of five protein products 
made up by proteins which can be categorized into two classes (Malewicz et 
al., 2003). Class I is made up of two proteins: NFκB1 (P50) and NFκB2 (p52) 
with NFκB1 and NFκB2 being synthesized from p105 and p100 precursors 
respectively. Class II is made up of three proteins: Rel A (p65), Rel B and 
cRel (Dabek et al., 2010; Kucharczak et al., 2003). Proteins of the NFκB 
family share identical motif at the N-terminal Rel homology                                     
domain (RHD) which allows them to bind to each other to form dimers, 
migrate into the nucleus and bind to DNA for the regulation of target genes 
(Kucharczak et al., 2003; Kutuk and Basaga, 2003). The C-terminal of these 
proteins is important for the regulation of the transcription activity 




1.4.2. NFκB activation 
In normal, unstimulated cells, NFκB is localized in the cytosol as a 
homodimer or heterodimer of two proteins, sequestered by Inhibitor of κB 
(IκB) (Kucharczak et al., 2003; Zhu et al., 2001). The different combinations 
of subunits in dimers would determine the type of genes that would be 
regulated (Kucharczak et al., 2003). The most predominant form of dimer seen 
at the cytosol is made up of p50 and p65 (Zhu et al., 2001; Miyamato and 
Verma, 1995). When bound, IκB blocks the nuclear localization sequence of 
NFκB, resulting in NFκB being inactive (Baker et al., 2011; Schultz and 
Harrington, 2003). In the classical pathway of NFκB activation, IκB would 
have to be phosphorylated by IκB Kinase (IKK) on specific residues, which in 
turn gets activated by cytokines or Pathogen-associated molecular pattern 
(PAMPs) (Baker et al., 2011). IKK could thus, regulate NFκB activation 
through its action on IκB (Chai and Liu, 2007; Varfolomeev and Ashkenazi, 
2004). Once phosphorylated, IκB gets ubiquitinated and subsequently, 
degraded by 26S proteasome (Mendes et al., 2009; He and Ting, 2002). NFκB, 
when released following IκB degradation, gets unmasked and translocates into 
the nucleus where it binds to DNA at the kB sequence motifs, regulating the 
transcription of specific target genes. To date, NFκB is known to be able to 
control the regulation of hundreds of genes (Kucharczak et al., 2003). NFκB 
could also trigger the synthesis of IκB, activating a negative feedback loop 
which helps to keep NFκB activity in check (Kucharczak et al., 2003). 
IKK, which plays a crucial role in NFκB regulation, exist as a multimeric 
complex. It is made up of three subunits, including two catalytic subunits 
IKKa and IKKb and one regulatory subunit NEMO (IKKy) (Vereecke et al., 
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2009; He and Ting, 2002; Harhaj et al., 2000; Mercurio et al., 1997). NEMO 
and IKKb are found to be essential for inflammation to occur (Baker et al., 
2011; Pasparakis et al., 2006). NFκB could not be activated following TNF 
stimulation in the absence of NEMO (Yamaoka et al., 1996). Deletion of 
NEMO in endothelial cell resulted in the abolishment of ICAM-1 expression. 
NEMO deficient endothelial cell also showed reduced level of TNFα and 
MCP-1, demonstrating the importance of NEMO in inflammatory response 
(Baker et al., 2011). Similarly, cells deleted of IKKb showed a lack of 
response in NFκB activity following TNF stimulation (Li et al., 1999; Tanaka 
et al., 1999). Mice model that lacked IKKb died in the embryonic stage due to 
liver degeneration as a result of excessive hepatocyte apoptosis (Monaco and 
Paleolog, 2004).  
 
1.4.3. NFκB stimulation 
NFκB can be induced by various stimuli, including cytokines, LPS, ultraviolet 
(UV) radiation, TNFα and ox-LDL,with activation being rapid and short 
lasting (Dabek et al., 2010; Kutuk and Basaga, 2003). This transient activation 
of NFκB allows for an appropriate level of response to be elicited following 
stimulation. Although NFκB could be activated by many stimuli, the eventual 
NFκB response following the stimulation would depend on the cell type and 
type of stimuli (Monaco and Paleolog, 2004). For instance, once stimulated 
under stress, NFκB would shuttle from the cytoplasm into the nucleus where it 




Another way in which NFκB can be stimulated is through the extrinsic death 
receptor TNFα. In the presence of a death signal, TNFα binds to TNFR1. The 
interaction of TNF receptor associated death domain protein (TRADD) with 
TNFR associated factor 2 (TRAF2) and Receptor Interacting Protein 1 (RIP1) 
instead of with Fas associated death domain (FADD) and caspase 8 would 
activate the NFκB survival mechanism (Oeckinghaus et al., 2011). As the 
absence of TRAF2 would prevent TNF-induced NFκB activation, TRAF2 is 
thought to play an essential role in the activation of NFκB (Rothe et al., 1995). 
RIP, when recruited, may activate IKK and thus, degrade IκB, allowing for the 
migration of active NFκB into the nucleus (Devin et al., 2000). TRAF2 is 
thought to be involved in the recruitment of IKK while RIP activates IKK 
(Devin et al., 2000). 
 
1.4.4. Roles of NFκB 
As mentioned previously, NFκB has control over many genes and is known 
for its role in inflammation, cell survival and cell apoptosis.  
1.4.4.1. Inflammation 
As part of the immune system, inflammation is an important defense against 
pathogens and damaged cells (Sprague and Khalil, 2009). Inflammation can be 
stimulated by various factors, including cellular microparticles, coagulation 
factors, heat shock proteins, oxygen radicals, infectious agents and adipokines 
(Sprague and Khalil, 2009). During an infection, PAMPs are recognized by 
host cells which in turn, release cytokines (Baker et al., 2011). These 
inflammatory cytokines lead to the activation of NFκB which activates 
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macrophages, the first line of immune defense (Baker et al., 2011). NFκB also 
activates its target genes and mediates cell proliferation, amplifying the 
immune response (Baker et al., 2011). Other inflammatory genes which are 
known to be downstream of NFκB include ICAM-1, MCP-1, TNF-a, A20 and 
MMP-9 (Dabek et al., 2010). 
1.4.4.2. Cell survival 
NFκB has also been widely studied on its function in promoting cell survival. 
The absence of an active NFκB resulted in the apoptosis of hepatic cells, 
causing embryonic lethality (Beg et al., 2002). Similarly, an experiment 
carried out using transgenic mice which expressed NFκB inhibitor showed 
significant increase in the level of apoptosis following infarction, suggesting 
the importance of NFκB in promoting cell survival (Misra et al., 2003). NFκB 
is known to play a role in cell survival through the regulation of i) cell death 
suppressing genes and ii) apoptotic genes (Dabek et al., 2010; Ren et al., 2007). 
i) Cell death suppressing genes 
NFκB promotes cell survival through various mechanisms, one of which is 
through up-regulating the transcription of cell death suppressing genes 
(Morotti et al., 2006; Burstein and Duckett, 2003). Examples of cell death 
suppressing target genes of NFκB include A20 (Cooper et al., 1996) and 
Inhibitor of Apoptosis Protein (IAP) (Schultz and Harrington, 2003; Stehlik et 
al., 1998). These specific targets of NFκB are shown to be protective against 
cell death.  
A20, a downstream target of NFκB, is a gene which encodes for an 80 kDa 
zinc finger protein found in the cytoplasm of multiple cell types (Lademann et 
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al., 2001). It has a low basal expression but is quickly induced upon 
stimulation (Vereecke et al., 2009). A20 is an ubiquitin-editing protein, with 
both deubiquitinating and ubiquitinating enzyme activity mediated by its N-
terminal and C-terminal respectively. Through its deubiquitinating and 
ubiquitinating activity on RIP1, A20 is found to be able to suppress the 
activation of NFκB, thus establishing a negative feedback loop (Won et al., 
2010; Vereecke et al., 2009). In mice that did not express A20, severe 
inflammation developed as they were not able to curb TNF-induced NFκB 
activation (Li et al., 2006; Lee et al., 2000).  
A20 is also seen as an anti-apoptotic protein as the over-expression of A20 
prevented extrinsically-induced apoptosis in various cell-types (Won et al., 
2010; Storz et al., 2005).  In contrast, mouse model with A20 knocked out are 
found to be more susceptible to apoptosis induced via TNF (Vereecke et al., 
2009; Lee et al., 2000). However, the exact molecular mechanism as to how 
A20 inhibits extrinsically-induced apoptosis is still unknown although the 
ubiquitin-editing activity of A20 is thought to play a role (Vereecke et al., 
2009).  
ii) Apoptotic genes 
In contrast, NFκB could also promote cell survival through the inhibition of 
apoptotic genes, disrupting the apoptosis-proliferation balance (Lee et al., 
2008). NFκB inhibition could result in the up-regulation of apoptotic genes, 
including Bax (Lee et al., 2008).  
Therefore, once NFκB is stimulated by TNF, various proteins which interfere 
with the apoptotic pathway at different levels would be stimulated, preventing 
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apoptosis from occurring (Malewicz et al., 2003). NFκB could thus, hamper 
TNF-induced cell death through regulation of various anti-apoptotic genes 
(Varfolomeev and Ashkenazi, 2004; Deng et al., 2003). With it pro-survival 
ability, NFκB is seen as an important anti-apoptotic molecule (Kucharczak et 
al., 2003). 
1.4.4.3. Cell apoptosis 
However, some studies have also suggested pro-apoptotic activity of NFκB. 
Studies have shown the ability of NFκB to induce Fas ligand (FasL) 
expression directly thus, promoting apoptosis in mature T cells during 
activation-induced cell death (AICD) (Kasibhatla  et al., 1999). Another study 
reported an increase in apoptosis-promoting p53 and c-Myc expression 
following NFκB stimulation (Qin et al., 1999). Other studies have also shown 
that excessive activation of NFκB would result in apoptosis. These studies 
were validated with NFκB inhibitors, suggesting the role of NFκB in the 
induction of apoptosis (Chopra et al., 2008). A study done by Hamid and his 
team reported a reduction in apoptotic level following chronic inhibition of 
NFκB in mice after coronary ligation (Hamid et al., 2011). Furthermore, it has 
been demonstrated that within an hour following TNF stimulation, the 
TRADD-RIP1-TRAF2 complex which was initially formed to activate NFκB 
could dissociate to activate the caspase pathway, initiating apoptosis 
(Oeckinghaus et al., 2011).   
Whether a cell would survive or undergo cell death would depend on the cell 
type, the cell environment and the type of apoptotic stimuli (Chopra et al., 
2008; Gozal et al., 2002; Zhu et al., 2001), although in majority of cells, NFκB 
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plays a role in cell survival through the antagonization of TNF-induced 
apoptosis (Won et al., 2010; Hayden and Ghosh, 2008). 
 
1.4.5. Link to diseases 
Given its control over the many genes downstream, discrepancies in NFκB 
signaling would result in various abnormalities. In fact, any defect in NFκB 
regulation would result in a variety of diseases (Vereecke et al., 2009). 
Diseases associated with NFκB regulation dysfunction include autoimmune 
diseases such as multiple sclerosis and Crohn’s disease (Dabek et al., 2010). 
Diseases with inflammatory causes, such as cancer, diabetes, rheumatoid 
arthritis and atherosclerosis also showed evidences of prolonged NFκB 
activation (Dabek et al., 2010; Yuan et al., 2010). NFκB activation is seen as 
the cause of the anti-apoptotic ability of cancer cells (Mori et al., 2002; Rayet 
and Gelinas, 1999) while chronic macrophage activation due to prolonged 
NFκB activation leads to diabetes and rheumatoid arthritis (Baker et al., 2011). 
In acute coronary syndromes, there is persistent activation of NFκB by 
cytokines which are synthesized by NFκB in the first place (Dabek et al., 
2010). Prolonged NFκB activation has also been associated with asthma and 
inflammatory bowel disease (Monaco and Paleolog, 2004).  
With evidences showing the role of NFκB in these diseases, NFκB is seen as 
an attractive therapeutic target for the treatment of these diseases (Chopra et 
al., 2008), with NFκB inhibitors being the main focus of companies (Vereecke 




1.4.5.1. Role in Atherosclerosis 
NFκB has been associated with atherosclerosis following detection of its 
active state within the nuclei of macrophages in lesions (Kutuk and Basaga, 
2003; Brand et al., 1996) and within human plaques (Brand, 1997). In fact, in 
unstable atherosclerotic plaques, NFκB activity is found to be elevated 
(Ritchie, 1998). When NFκB signaling was disabled, recruitment of 
macrophage and plaque formation was found to be suppressed, highlighting 
the role of NFκB in atherosclerotic progression. This can be observed using 
animal models, where foam cells were almost absent in the lesions of p50 
knockout mice (Ferreira et al., 2007). This observation can be further 
confirmed by another study which reported a reduction in lesion size following 
the induction of A20, a negative regulator of NFκB. Similarly, mice with 
insufficient A20 showed a larger lesion area compared to the control mice 
(Wolfrum et al., 2007). These observations further validated the importance of 
NFκB in both the initiation and progression of atherosclerosis (Cirillo et al., 
2007).  
Inflammation is known to play an important role in all stages of 
atherosclerosis (Dabek et al., 2010). Genes which are known to play a role in 
the initiation and progression of atherosclerosis can be regulated by NFκB 
(Baker et al., 2011). Factors such as TNFα and stress which are known to 
stimulate the initiation of atherosclerosis are also known to stimulate NFκB 
activation. Once NFκB translocates into the nucleus, it could up-regulate the 
expression of downstream inflammatory mediators resulting in atherosclerosis 
development (Kutuk and Basaga, 2003). Examples of these downstream 
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targets of NFκB include ICAM-1, MCP-1, cytokines, MMPs and TF (Sprague 
and Khalil, 2009; Boyle, 2005).  
Expression of adhesion molecules such as ICAM-1 and chemokines such as 
MCP-1, established to play important roles in the initiation of atherosclerosis, 
are known to be regulated by NFκB (Dabek et al., 2010; Cirillo et al., 2007; 
Kutuk and Basaga, 2003). The level of CAMs in serum is shown to have a 
strong correlation with CAD (Ridkler  et al., 1998). ICAM-1 is thought to play 
a crucial role in the translocation of monocytes to the site of lesion during the 
initiation of atherosclerosis (O Brien et al., 1996). The knockout of ICAM-1 in 
animal mouse model protected them from atherosclerosis. Knockout of MCP-
1, a potent chemoattractant which allows the entry of monocytes into the 
arterial intima, in mice also showed similar suppression of atherosclerosis, 
demonstrating the importance of these molecules in atherosclerosis initiation 
(Boyle, 2005). NFκB is thus, an important contributor to the initiation of 
atherosclerosis through its control over adhesion molecules and 
chemoattractants (Kutuk and Basaga, 2003). 
Proinflammatory cytokines are also known to play a role in both plaque 
development and plaque rupture (Dabek et al., 2010). These inflammatory 
mediators are able to cause significant up-regulation of MMPs, especially in 
macrophages found in lesions (Halvorsen et al., 2008; Boyle, 2005). Research 
has shown that macrophages within lesions are a major source of MMPs 
(Libby et al., 2010; Newby, 2007). MMPs regulated by NFκB play a role in 
extracellular matrix degradation, leading to thinning of the fibrous cap and 
eventually, plaque rupture (Dabek et al., 2010; Halvorsen et al., 2008; Boyle, 
2005). Not surprisingly, MMPs are found to be expressed at greater levels in 
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unstable versus stable plaques and are indications of high risk atherosclerosis 
(Halvorsen et al., 2008; Kunte et al., 2008). On top of its breakdown effects, 
MMPs are able to contribute to atherosclerosis through platelet activation 
(Halvorsen et al., 2008). In addition, MMPs have also been associated with 
oxidative stress which is another risk factor of atherosclerosis (Halvorsen et al., 
2008). The number of MMPs involved in atherosclerosis is increasing, with 
MMP-9 being identified as one of the major contributors (Van den Borne et al., 
2009; Boyle, 2005). Tissue samples obtained from ruptured lesions showed 
higher levels of MMP-9 when compared to non-ruptured lesions (Van den 
Borne et al., 2009). A correlation between MMP-9 level in plasma and risk of 
CAD death was also identified by Blankenberg and his team (Blankenberg et 
al., 2003).  
NFκB also has a binding site in the promoter of TF. As the initiator of blood 
coagulation, TF would bind to Factor VIIa (FVIIa) to form TF: FVIIa complex 
which would in turn, activate the coagulation protease cascades (Mackman, 
2004). TF thus, plays a crucial role in thrombosis through the promotion of 
coagulation (Calabro et al., 2011; Monaco and Paleolog, 2004). TF level is 
found to be higher in patients with unstable angina than patients with stable 
angina (Zoldhelyi, 2001). Other than its role in the coagulation cascade, TF is 
also known to initiate intracellular signaling within macrophages which could 
contribute to prolonged inflammation (Cai et al., 2007).                                                                                                        
With the detection of active NFκB in lesions and the control NFκB has over 
targets which are known to play important roles in both atherosclerosis 
initiation and progression, it is of no doubt that NFκB is a major contributor to 
both initiation and progression of atherosclerosis (Kutuk and Basaga, 2003). 
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NFκB is in fact, seen as a potential therapeutic target for atherosclerotic 
conditions through the prevention of lesion progression (Dabek et al., 2010; 
Kutuk and Basaga, 2003). Quinapril, used for the treatment of hypertension 
and heart failure, could suppress NFκB activation and reduce macrophage 
infiltration (Hernandez-Presa et al., 1998). Cholesterol lowering drugs in the 
market such as atorvastatin and simvastatin are also found to be able to 
stabilize plaques through the inhibition of NFκB (Hernandez-Presa et al., 2003; 




Cell elimination can occur through various processes, including via apoptosis, 
necrosis, autophagy and more recently, necroptosis (Vandenabeele et al., 
2010).  Of these, apoptosis is one of the best characterized forms of cell death 
(Reeve et al., 2005). Coined in 1972 by Kerr, Wyllie and Currie (Kerr et al., 
1972), apoptosis is a term used to describe a mode of cell death which occurs 
in a systematic manner. Unlike necrosis, apoptosis is a tightly regulated 
process whereby cells die in an orderly manner, as observed in Caenorhabditis 
elegans (Vandenabeele et al., 2010; Schultz and Harrington, 2003; Sulston and 






1.5.1. Characteristics of apoptosis 
Apoptosis can be recognized from morphological characteristics which 
include cells rounding up and retracting from neighbouring cells, blebbing of 
membrane, chromatin condensation and DNA fragmentation (Kutuk and 
Basaga, 2006; Choy et al., 2001; Kockx and Herman, 2000; Wyllie et al., 
1980). Apoptotic cells are eventually removed by phagocytosis (Lee and 
Gustafsson, 2009; Choy et al., 2001). This tightly controlled process ensures 
that apoptotic cells are removed with minimal disruptions to surrounding cells 
(Lee and Gustafsson, 2009; Taylor et al., 2008). 
 
1.5.2. Roles of apoptosis 
Apoptosis is an energy requiring process that is vital for the proper functioning 
of many biological processes. It is required for embryogenesis, homeostasis 
through counterbalancing cell proliferation, removal of detrimental or 
unwanted cells, morphogenesis, organ development, and normal cell turnover 
(Hossini and Eberle, 2008; Kutuk and Basaga, 2006; Liu and Lin, 2005; 
Schultz and Harrington, 2003).  
 
1.5.3. Caspases  
Caspases, a family of cysteine proteases, play a major role in apoptosis. In 
healthy cells, caspases exist as inactive precursor enzymes (Taylor et al., 
2008). Initiator caspases such as caspase 8 and 9 are found upstream of 
effector caspases such as caspase 3 (Strasser et al., 2000). Dimerization or 
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specific proteolytic cleavage in the presence of apoptotic stimuli activates 
caspases which in turn, cleave specific substrates to cause characteristic 
morphological and biochemical changes (Reeve et al., 2005).   
 
1.5.4. Apoptotic pathways 
Apoptosis can be triggered by both external and internal factors (Staercke et 
al., 2003). Thus, apoptosis can occur via two main pathways, namely the i) 
extrinsic and the ii) intrinsic pathway, though iii) cross-talk between these two 
pathways is also possible. 
i) Extrinsic pathway 
The extrinsic pathway is activated by extracellular death signals, where a 
death ligand binds onto the transmembrane receptor located on the cell surface 
(Schultz and Harrington, 2003). These death ligands, each characterized by a 
conserved cysteine-rich motif, are from the TNF superfamily. The death 
receptor family includes Tumor Necrosis Factor Receptor 1 (TNFR1), Fas, 
Death Receptor (DR) 3, DR6 and nerve growth factor receptor (Li and Yuan, 
2008). These death receptors possess a ligand-interacting domain found 
extracellularly, a transmembrane domain and a death domain found 
intracellularly (Thorburn, 2004).  
Of these, one of the best characterized death receptors is the Fas receptor. The 
binding of FasL to Fas results in the trimerization of the receptor, forming a 
Death Domain (DD) (Ashkenazi and Dixit, 1998). Adaptor protein FADD 
then gets recruited and binds to the DD. FADD which possesses a Death-
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Effector Domain (DED) allows the recruitment of pro-caspase 8, forming the 
Death-inducing Signaling Complex (DISC) (Juo et al., 1998). Caspase 8, when 
activated, cleaves downstream caspases, including caspase 3 which causes the 
cleavage of caspase-activated deoxyribonuclease (CaD) inhibitor upon 
activation. Endonuclease CaD when released, enters into the nucleus, 
degrading chromosomal DNA and thus, resulting in DNA fragmentation 
(Schultz and Harrington, 2003; Choy et al., 2001; Sakahira et al., 1998). 
Another known target of caspase 3 is poly (ADP-ribose) polymerase (PARP), 
a DNA repairing enzyme (Choy et al., 2001). The Fas death pathway is a 
major apoptotic mechanism in atherosclerosis (Tewari  et al., 1995).  
Another well-characterized death receptor is TNFR1. Similar to Fas, the 
binding of TNFα to TNFR1 exposes the DD, recruiting TRADD. FADD then 
binds to TRADD via its DD and recruits pro-caspase 8, activating the caspase 
cascade (Hsu et al., 1998).  
However, cell death does not always occur following the activation of death 
receptors. Death receptors which are involved in apoptosis could also lead to 
the activation of NFκB. Depending on the cell type and the environment, 
NFκB could either induce cell death or promote cell survival (Zhu et al., 2001).  
ii) Intrinsic pathway 
The intrinsic pathway, triggered by cytotoxic drugs, stress, radiation and DNA 
damage (Li and Yuan, 2008; Kutuk and Basaga, 2006; Choy et al., 2001), 
involves the mitochondria of the cell.  
When there is an increase in the mitochondria outer membrane permeability 
(MOMP), cytochrome c which is localized in the intermembrance space, is 
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released into the cytosol (Hossini and Eberle, 2008; Gottlieb, 2000; 
Ghafourifar et al., 1999) where it binds to apoptosis protease-activating factor-
1 (Apaf-1) and dATP/ATP to form an apoptosome following oligomerization 
(Chinnaiyan, 1999; Zou et al., 1997). The apoptosome is thus, a multiprotein 
complex (Hossini and Eberle, 2008; Chinnaiyan, 1999). Apaf-1 contains a 
caspase activation and recruitment domain (CARD) which allows it to recruit 
pro-caspase 9. Activated caspase 9 then activates downstream caspase 3, 
leading to cell death (Schultz and Harrington, 2003; Qin et al., 1999). 
Other than cytochrome c, mitochondria could also release other pro-apoptotic 
factors such as second mitochondria-derived activator of caspases 
(Smac/DIABLO), endonuclease G (Endo G) and apoptosis inducing factor 
(AIF) into the cytosol under stress (Lee and Gustafsson, 2009; Hossini and 
Eberle, 2008; Shiozaki et al., 2004). 
Permeability of the mitochondria membrane, which determines the release of 
pro-apoptotic proteins, is dependent on the B cell lymphoma-2 (Bcl-2) protein 
family (Chipuk and Green, 2008). Bcl-2 family of protein can be divided into 
2 categories:  a) anti-apoptotic and b) pro-apoptotic. Whether a cell will 
survive or undergo cell-death would depend on the balance of anti- and pro-
apoptotic Bcl-2 protein members (Chipuk and Green, 2008; Hossini and 
Eberle, 2008; Choy et al., 2001).  
a) Anti-apoptotic Bcl-2 family 
Anti-apoptotic Bcl-2 protein members possess 4 conserved Bcl-2 homology 
(BH) motifs. Members in this category include Bcl-2 and Bcl-XL. Anti-
apoptotic Bcl-2 family members prevent apoptosis by inhibiting pore opening 
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and depolarization of the mitochondrial membrane which would prevent the 
release of pro-apoptotic proteins from the mitochondria into the cytosol (Lee 
and Gustafsson, 2009; Choy et al., 2001).  
b) Pro-apoptotic Bcl-2 family 
Pro-apoptotic Bcl-2 protein members possess either 3 BH domains (Bax and 
Bak) or only a BH3 domain (BID and Bad). In the event of stress, pro-
apoptotic Bcl-2 protein members oligomerize within the outer mitochondrial 
membrane, permeabilizing the membrane with pores which are large enough 
for the release of pro-apoptotic proteins like cytochrome c (Lee and 
Gustafsson, 2009; Chipuk and Green, 2008; Marzo et al., 1998). BH3 domain 
only proteins are thought to function as sensors for cellular stress and are able 
to induce cell death by binding to pro-apoptotic Bcl-2 family members, 
forming heterodimers and neutralizing the anti-apoptotic Bcl-2 proteins (Lee 
and Gustafsson, 2009; Hossini and Eberle, 2008; Schultz and Harrington, 
2003).  
iii) Cross-talk  
When activated, caspase 8, a component of the extrinsic pathway, could 
activate the intrinsic pathway by cleaving BH3 only Bcl-2 protein, BH3 
interacting-domain death agonist (BID). BID, which is inactive in the cytosol 
under normal conditions, gets cleaved by caspase 8 at aspartate 60 to form a 
15kDa truncated BID (tBID).  tBID translocates into the mitochondria where it 
activates the mitochondria dependent cell death pathway, causing the release 
of cytochrome c (Kutuk and Basaga, 2006; Littlewood and Bennett, 2003; Li 
et al., 1998). The cross-talk between these two pathways allows for the 
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amplification of the death signal (Lee and Gustafsson, 2009; Li and Yuan, 
2008; Slee et al., 2000). 
 
1.5.5. Link to diseases 
Given the role of apoptosis in vital processes, dysregulation of apoptosis is 
linked to many diseases. In fact, there is an increasing recognition of diseases 
which arise due to apoptotic disorder (Staercke et al., 2003). Diseases linked to 
apoptosis dysregulation include cancer, neurogenerative diseases, diabetes and 
atherosclerosis (Kutuk and Basaga, 2006; Guevera et al., 2001). 
1.5.5.1. Role in Atherosclerosis  
With accumulating evidences, apoptosis is now known as a key event in 
atherosclerosis (Lee and Gustafsson, 2009; Staercke et al., 2003). It has been 
observed that the frequency of apoptosis occurring in atherosclerotic plaques 
is greater compared to the frequency of apoptosis in normal vessels (Stoneman 
and Bennett, 2004). A correlation between the frequency of apoptosis and the 
stage of atherosclerotic lesions was similarly noted (Clarke and Bennett, 2009; 
Mercer et al., 2007; Guevera et al., 2001; Kockx et al, 1998).  
In addition to the above observations, targets which play a role in apoptosis 
have also been detected at atherosclerotic sites. Genes like Bax, p53 and Fas 
which are known to induce apoptosis were found to be up-regulated in 
atherosclerotic plaques (Kockx, 1998). Fas was also detected in foam cells 
found in coronary arteries (Filippatos et al., 2004). Moreover, hearts infected 
with soluble Fas, a FasL competitive inhibitor, showed improvement in both 
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cardiac function and survival (Li et al, 2004). Activated caspases were 
detected in the myocardium of patients with end-stage heart failure (Narula  et 
al., 1996). Nuclear fragments, thought to be remnants of apoptosis could also 
be found within lipid core (Geng and Libby, 1995). Even in animal models of 
hypercholesterolemia, apoptotic vascular cells were detected (Nigris et al., 
2003; Hasdai et al., 1999). These accumulating evidences demonstrate the 
involvement of apoptosis in heart diseases.  
The role of apoptosis in atherosclerosis is seen as complex as it is thought that 
apoptosis could be both beneficial and detrimental to atherosclerotic 
progression. Efferocytosis, which is the efficiency of phagocytosis of 
apoptotic cells, would determine if apoptosis would result in a reduction in 
cellularity or an increase in necrotic core size (Seimon and Tabas, 2009). In 
the early stages of atherosclerosis, apoptosis could reduce lesion development 
due to high efferocytosis. The clearance of apoptotic cells in early 
atherosclerosis prevents the build up of apoptosized cells within the lesion, 
keeping the size of lesion at the minimal (De Lorenzo, 2010; Wilson, 2010; 
Savill and Fadok, 2000). However, at later stages of atherosclerosis, 
efferocytosis would be reduced due to plaque formation (Kockx and Knaapen, 
2000). Apoptosis at this stage would then promote atherosclerotic progression. 
The eventual consequences following apoptosis would therefore, depend on 
the type of cells involved, the site where apoptosized cells are located within 
the plaque and the stage of development of the plaque (Mercer at al., 2007; 
Kockx and Herman, 2000).  
All types of cells found within the lesion could undergo apoptosis, including i) 
endothelial cells, ii) vascular smooth muscle cells and iii) macrophages 
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(Guevera et al., 2001; Kockx et al., 1996). Apoptosis of cells within lesions 
can be initiated by different stimulus, including oxidative stress, cytokine 
exposure and DNA damage (Lee and Gustafsson, 2009). Apoptosis of these 
cells has been shown to play a role in both the initiation and progression of 
atherosclerosis (Choy et al., 2001). In fact, it has been proposed that the 
inhibition of apoptosis of these cells could be a potential therapeutic 
intervention in Coronary Artery Disease (CAD) (Halvorsen et al., 2008).  
i) Endothelial cells (EC) 
EC forms the inner lining of blood vessels and thus, apoptosis of EC could 
result in endothelial dysfunction, initiating atherosclerosis (Chai and Liu, 2007; 
Kutuk and Basaga, 2006). Apoptotic EC is seen as a key characteristic of 
advanced atherosclerosis (Filippatos et al., 2004; Geng and Libby, 1995) as 
the presentation of phosphatidylserine by apoptosized cells may promote 
coagulation (Guevera et al., 2001; Bombeli et al., 1997). EC apoptosis has also 
been suggested to play a role in the erosion and rupture of plaques (Staiger et 
al., 2009; Dimmeler et al., 2002). In patients with heart diseases, namely 
myocardial infarction and angina, high level of apoptotic endothelial cells was 
detected (Mutin et al., 1999).  
ii) Vascular Smooth Muscle Cells (VSMC) 
VSMC is seen as a source of collagen fibres. Apoptosis of VSMC would 
therefore, result in a decrease in plaque stability as loss of VSMC weakens the 
fibrous cap (Laufer et al., 2009; Halvorsen et al., 2008; Guevera et al., 2001; 
Kockx and Herman, 2000). Evidently, ruptured plaques possess low amount of 




Macrophages are scavenging bodies which form the main component of 
atherosclerotic plaques and they can be detected at all stages of atherosclerosis 
(Seimon and Tabas, 2009). Macrophages seemed to play a key role in 
atherosclerosis as plaque rupture sites consist mainly of macrophages 
(Littlewood and Bennett, 2003; Kolodgie et al., 2000). As reported, apoptosis 
within atherosclerotic plaques is mainly found in areas containing many foam 
cells which are known to be lipid laden macrophages (Kockx et al., 1998). The 
shoulder of lesions, found to contain the largest proportion of apoptotic cells 
are also made up of mostly macrophages (Ball et al., 1995). The collective loss 
of macrophages via apoptosis within plaques has been associated with Acute 
Coronary Syndrome (ACS) (Laufer et al., 2009). 
Apoptosis of macrophages within lesions would reduce the number of 
scavenging cells in the plaque (Kockx and Herman, 2000). Apoptosized cells, 
when not cleared would accumulate to form cellular debris (Kockx and 
Herman, 2000), leading to secondary necrosis and eventually, the buildup of a 
necrotic lipid core (Seimon and Tabas, 2009; Clarke and Bennett, 2009; 
Kockx and Herman, 2000) which is characterized by the presence of 
apoptosized macrophages, macrophage debris and inflammatory cytokines 
(Tabas, 2004; Ball et al., 1995). A correlation between the development of a 
necrotic core and the level of macrophage death is observed (Seimon and 
Tabas, 2009).  Similarly in animal models, a reduction in apoptosis of 
macrophages resulted in a matching reduction in necrotic core formation 
(Tabas, 2007). Vulnerable plaques are shown to be mainly made up of 
apoptosized macrophage foam cells (Laufer et al., 2009; Tabas, 2007) and thus, 
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it has been proposed that apoptosis of macrophages contributes to the 
vulnerability of a plaque (Laufer et al., 2009).  
Factors that contribute to macrophage apoptosis at these sites are still 
unknown although cytokines and oxidized lipids are suspected to play a role 
(Littlewood and Bennett, 2003). The mechanism of macrophages undergoing 
apoptosis in atherosclerotic lesions is also not yet fully understood (Tabas, 
2004) although apoptotic macrophages are found to express both Fas and FasL 
and that the Fas pathway is seen as a major death pathway contributing to 
atherosclerosis (Guevera et al., 2001; McCarthy and Bennett, 2000).  
Apoptosis of vascular cells within atherosclerotic plaques would affect plaque 
structure and stability (Kockx and Herman, 2000). The buildup of a necrotic 
core, due to poor efferocytosis following apoptosis, and weakened fibrous cap 
contribute to the formation of unstable plaques which are detected in advanced 
atherosclerotic stages (Nigris et al., 2003). Apoptosis could therefore, 
contribute to atherosclerosis through its effects on plaque stability which may 
eventually result in plaque rupture and thrombosis (Halvorsen et al., 2008; 
Nigris et al., 2003). Uncleared apoptotic bodies of any cell types, especially 
macrophages, might activate TF within the plaque, increasing blood 
thrombogenicity (Xu et al., 2009; Tabas, 2004; Greeno et al., 1996; Bach and 
Rifkin, 1990). In the event of a rupture, the core contents are released into the 
blood and thrombosis is much likely to occur due to the large amount of TF 
secreted in advanced plaque (Croce and Libby, 2007). Thrombus formed may 
block coronary arteries, restricting blood flow to the myocardium. Myocardial 
infarction and death may eventually occur following thrombus formation 
(Nigris et al., 2003; Kockx et al., 1998). Thus, apoptosis of vascular cells not 
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only contributes to atherosclerotic progression, but the eventual life-
threatening outcome as well (Nigris et al., 2003). 
In the absence of plaque rupture, apoptosis could also cause plaque erosion 
which could result in sudden cardiac death (Xu et al., 2009; Farb et al., 1996). 
In fact, eroded plaques account for approximately one-third the cause of acute 
thrombotic events (Xu et al., 2009; Farb et al., 1996).  
With the prominence of apoptosis in heart patients, anti-apoptotic proteins and 
caspase inhibitors are seen as potential therapeutic and preventive targets of 
heart diseases (Lee and Gustafsson, 2009).  
 
1.5.6. c-jun N-terminal Kinase (JNK) 
The mitogen-activated protein kinase (MAPK) is a cascade regulated via 
phosphorylation and is known to play a role in both cell death and cell survival 
(Iwaoka et al., 2006). JNK, a subfamily of the MAPK superfamily, plays a 
role in apoptotic regulation (Lin, 2003). Activated JNK is shown to be able to 
induce cell death via both extrinsic and intrinsic apoptotic pathway. In fact, 
other than the protease cascade, the kinase cascade, consisting of JNK, is also 
seen as a signaling pathway of apoptosis when cells are under stress or when 
exposed to various cytokines and toxic stimuli (Saeki et al., 2002; Ichijo, 
1999).  
In recent years, JNK has been associated with apoptosis, with prolonged JNK 
activation being seen as apoptosis initiating (Liu and Lin, 2005). Studies have 
suggested that JNK is required for TNF-induced apoptosis (Lademann et al., 
2001; Verheij et al., 1996). Mouse embryonic fibroblasts that were deficient in 
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JNK could resist apoptosis after being stimulated with UV radiation, 
demonstrating the importance of JNK in apoptosis (Stadheim et al., 2002; 
Tournier et al., 2000).  Similarly, the inhibition of JNK activation was found to 
suppress nerve growth factor (NGF) withdrawal-induced apoptotic effect in rat 
PC-12 pheochromocytoma cell (Liu and Lin, 2005).  
However, depending on the condition of the cells, cases of JNK being able to 
promote cell survival have also been reported (Kucharczak et al., 2003). Anti-
apoptotic effect of JNK was observed in tumor cells that are deficient in p53 
(Potapova et al., 2000). JNK1 and JNK2 deficient mice also showed increased 
apoptosis in their forebrain and hindbrain regions (Kuan et al., 1999). Whether 
JNK would induce apoptosis or protect cells from apoptosis would depend on 
the stimuli and the type of cells involved (Liu and Lin, 2005).  
1.5.6.1. Link to NFκB 
JNK cascade could be activated under environmental stress and by various 
cytokines, including TNF (Varfolomeev and Ashkenazi, 2004; Kucharczak et 
al., 2003). However, JNK activation by TNF is found to be inhibited by 
various genes regulated by NFκB, accounting for the transient JNK activation 
following TNF stimulation (Deng et al., 2003; De Smaele et al., 2001). One 
such target gene of NFκB involved in JNK suppression is A20 (Lademann et 
al., 2001). Similarly, the inhibition of these NFκB regulated genes results in a 
corresponding JNK activation following TNF stimulation. In the absence of 
NFκB in mouse embryonic fibroblast, continual JNK activation was observed 
following TNF stimulation (De Smaele et al., 2001), showing evidence of a 
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negative crosstalk between NFκB and JNK (Liu and Lin, 2005; Varfolomeev 
and Ashkenazi, 2004; Kucharczak et al., 2003; Stadheim et al., 2002). 
As mentioned previously, NFκB is known for its function in cell survival. One 
of the ways NFκB could promote cell survival is through the suppression of 
JNK (Tang et al., 2001). Mouse embryonic fibroblast which lacked NFκB 
undergoes TNF-induced apoptotic cell death more readily with the persistent 
JNK activation (Won et al., 2010). 
 
 
1.6. Rationale and purpose of study 
SAA, an acute phase protein, is found to be elevated not only in 
atherosclerosis, but also in conditions which are known risk factors of 
atherosclerosis. To date, however, whether SAA is an active participant or just 
a passive responder in the atherosclerotic process is still unclear. As an 
inflammatory disease, atherosclerosis occurs over a number of stages. The role 
of SAA in the various stages of atherosclerosis similarly, still remains obscure. 
Studies have been carried out to determine the role of SAA in atherosclerosis 
via the inflammatory pathway. However, most of these studies were carried 
out using monocytes. In this study, macrophages were used as they form the 
main constituent of atherosclerotic plaques. Apoptosis has been established to 
play an important role in atherosclerosis. Despite elevated SAA level in 
atherosclerosis, minimal research was conducted to determine the association 
between SAA and apoptosis. The few studies which showed the ability of 
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SAA to induce apoptosis provided no in-depth investigation on the mechanism 
through which apoptosis was induced. 
As both inflammation and apoptosis are known to contribute to various stages 
of atherosclerosis, we hypothesize that SAA could actively contribute to 
atherosclerosis through both the inflammatory and apoptotic pathway.  
 
Through this study, we sought to determine the role of SAA in contributing to 
atherosclerosis via these two pathways.  The specific aims of this study 
include: 
1) To determine the effect of SAA on inflammatory targets known to play 
important roles in atherosclerosis using RAW264.7 
2) To determine  
a. If SAA could induce apoptosis of RAW264.7; and if so, 
b. The mechanism through which apoptosis occurs 
 
With these objectives, we hope to find out more on the role of SAA in 


















2.1. Cell Culture 
Mouse macrophages, RAW264.7, obtained from American Type Culture 
Collection (ATCC, Manassas, Virginia, United States) were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% 
Fetal Bovine Serum (FBS), 100 units/ml penicillin and 100μg/ml 
streptomycin (all from Sigma Aldrich) in 5% CO2, 37oC. 
 
 
2.2. SAA treatment 
As the more dominant type of acute phase protein, this study was carried 
out using SAA1. Apo-SAA1 (Peprotech, Rocky Hill, New Jersey, United 
States) was dissolved in MilliQ water to a concentration of 1mg/ml and 
stored at -20oC. Appropriate volume of apo-SAA1 solution was then added 
to FBS free cell culture media to get SAA of various concentrations before 
they were added directly onto cells. 
 
 
2.3. NFκB inhibition 
RAW264.7 were seeded in 6-well plates at a density of 8x105 cells per 
well a day before the experiment. Cells were treated with 10μM Bay11-
7082 (Sigma Aldrich) for 1 h to ensure full inhibition of NFκB. After the 1 
h incubation period, Bay11-7082 was removed from each well and cells 
were washed twice with 1 x Phosphate Buffered Saline (PBS) to ensure the 
complete removal of Bay11-7082. Cells were then treated with FBS free 
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DMEM, which served as the control, or various concentrations of SAA 
and incubated for various time-durations accordingly. 
 
 
2.4. RNA isolation 
RAW264.7 were seeded in 6-well plates at a density of 8x105 cells per 
well. On the following day, cells were treated with either DMEM (FBS 
free), which served as a control, 40μg/ml or 80μg/ml of SAA for various 
time-durations (1 h, 3 h, 6 h or 24 h). Cell media were removed and the 
cells were rinsed with 1 x PBS before RNA was extracted.  
 
Total RNA was extracted from RAW264.7 using RNeasy Mini Kit 
(Qiagen). According to the protocol, cells were lysed in 350μl of Buffer 
RLT containing 1% β-mercaptoethanol. The lysate was passed through a 1 
ml pipette tip for up to 30 times to ensure homogeneity. One volume of 70% 
ethanol was then added to the homogenized lysate and further mixed 
before the mixture was added onto a RNeasy mini column. The columns 
were subjected to centrifugation at 13,000 rpm for 15s. The flow-through 
obtained was then discarded and the column was further washed with 
Buffer RW1. The centrifugation was repeated and the columns were 
washed two more times with Buffer RPE before they were given a final 
centrifugation at 13,000rpm for 2 min to ensure that the silica-gel 
membrane was fully dried. Finally, about 30-50μl of RNase-free water was 
45 
 
added onto the membrane directly before the tubes were centrifuged at 
13,000rpm for 1 min to acquire RNA from each tube. 
 
The RNA yield obtained was then quantitated using the Nanodrop ND-
1000 (Thermo Fisher Scientific Inc. Waltham, MA, USA). 1μg RNA was 
used to synthesize first strand cDNA in a single step using a first strand 
cDNA synthesis kit (Fermentas). Briefly, 1μg of RNA was added to 4μl of 
5x Reaction Mix and 2μl of Maxima Enzyme Mix for a 20μl reaction mix. 
The mixture was then incubated at 25oC for 10 min, 50oC for 15 min and 
then finally 85oC for 5 min to ensure reaction termination. 
 
 
2.5. Real-Time Polymerase Chain Reaction (PCR) 
Real-time PCR was carried out using LightCycler 480 system (Roche).  
10μl of real-time PCR mixture contained the following: 5 μl of 2x 
LightCycler 480 SYBR Green I Master (Roche), 0.5 μM of forward and 
reverse primer, 50ng template cDNA and RNase free water.   
 
The mixture was first subjected to 95oC for 10 min to activate the FastStart 
Taq DNA Polymerase and to denature the cDNA. The mixture was then 
subjected to the following conditions for amplification: 95oC for 10s to 
allow for denaturation; 62oC for 10s for annealing and finally 72oC for 15s 
for extension. Primers (First Base, Singapore) used are listed below (Table 
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1). The number of amplification cycle was set at 45. The threshold cycle 
(CT) was eventually determined by the accompanied LightCycler 480 
software (Roche). Relative fold change was generated using the same 
software using standard-curve derived efficiencies. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an endogenous control to 
normalize each target sample. 
Table 1: Real-Time PCR Primer sets 
Target  gene PCR Primer (5′-3′) 
  
ICAM-1 5′-TGT TTC CTG CCT CTG AAG C-3′ 
5′-CTT CGT TTG TGA TCC TCC G-3′ 
MCP-1 5′-CCC ACT CAC CTG CTG CTA CT-3′ 
5′-TCT GGA CCC ATT CCT TCT TG-3′ 
MMP-9 5′-TGT CTG GAG ATT CGA CTT GAA GTC-3′ 
5′-TGA GTT CCA GGG CAC ACC A-3′ 
TF 5′-TCA AGC ACG GGA AAG AAA AC-3′ 
5′-CTG CTT CCT GGG CTA TTT TG-3′ 
TNFα 5′-ATG AGC ACA GAA AGC ATG ATC-3′ 
5′-TAC AGG CTT GTC ACT CGA ATT-3′ 
Fas 5′-CCC ATG CAC AGA AGG GAA GGA GT-3′ 
5′-TTC CAT GTT CAC ACG AGG CGC AG-3′ 
BCL-2 5′-GGA TAA CGG AGG CTG GGA TGC CT-3′ 
5′-TCG ACC TCA CTT GTG GCC CAG-3′ 
A20 5′-AAA CCA ATG GTG ATG GAA ACT G-3′ 
5′-GTT GTC CCA TTC GTC ATT CC-3′ 
GAPDH 5′- GAC GGC CGC ATC TTC TTG TGC -3′ 




2.6. Protein extraction 
RAW264.7 were seeded in 6-well plates at a density of 8x105 cells per 
well. On the following day, cells were treated with either DMEM (FBS 
free), which served as a control or 80μg/ml of SAA for various time-
47 
 
durations. Cell media were removed and the cells were rinsed with ice cold 
1 x PBS before protein was extracted. 
 
Cells were lysed with lysis buffer which contained the following: 62.5mM 
Tris-HCl (pH6.8); 2% Sodium Dodecyl Sulfate (SDS); 10% glycerol; 
50mM Dithiothreitol (DTT) and Proteinase Inhibitor cocktail (Roche, 
Indianapolis, USA). The lysate mixture was then repeatedly passed 
through a 27-gauge needle to ensure homogenization. After which, the 
protein lysates were spun at 14, 000rpm at 4oC for 10 min. The 
supernatants were collected and the amount of protein extracted from the 
cells in each well was measured against standards of known concentration 
using Dc Protein Assay (Bio-Rad).  
 
 
2.7. Western blot 
For each sample, 40μg of protein were loaded and separated by 12% SDS-
Polyacrylamide gel electrophoresis (SDS-PAGE) gel. After being 
separated according to their molecular weight, the proteins were 
transferred onto a nitrocellulose membrane at 85 V for 2 h. After which, 
the nitrocellulose membranes were blocked with 5% skimmed milk in 
Tris-buffered saline with 0.1% Tween 20 (TBST) for 1 h. The membranes 
were then incubated with primary antibodies at suitable dilutions for 1 h at 
room temperature or overnight at 4oC. GAPDH was used as an internal 
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control and the proteins Poly (ADP-ribose) Polymerase (PARP), Caspase 3, 
Caspase 8, Caspase 9, B Cell Lymphoma-2 (Bcl-2), A20, c-Jun N-terminal 
kinases (JNK) and phosphorylated JNK (p-JNK) were probed for. Rabbit 
monoclonal antibodies of the above targets (all from Cell Signaling) were 
all used at a concentration of 1:1000. After several washes, the membranes 
were then incubated with diluted secondary antibody for another hour at 
room temperature. Anti-rabbit secondary antibody coupled to horseradish 
peroxidase (HRP) (Dako, Denmark) was used at a concentration of 1:2000. 
The blots were washed several times before they were developed with 
SuperSignal West Pico Chemiluminescent Substrate (Pierce) and exposed 
with Clear Blue X-ray film (Pierce).  
 
 
2.8. MTT assay 
3-(4,5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) is 
an assay used to detect for cell viability. Viable cells contain mitochondrial 
dehydrogenase enzyme which is able to cleave the pale yellow MTT 
tetrazolium rings to produce dark blue, non-water soluble formazan 
crystals. Therefore, dark blue crystals can only be accumulated by viable 
cells. The formazan product is then solubilized in suitable solvent to allow 
for the quantification of viable cells via a simple colorimetric assay, 
whereby the percentage of viability is directly proportional to the amount 




Approximately 5x103 cells were seeded into each well of a 96-well plate. 
On the following day, cells were treated, in triplicates, with various 
concentrations of SAA: 5, 10, 20, 40 and 80μg/ml in FBS free DMEM. 
FBS free DMEM was used as a control. As MilliQ water was used to 
dissolve Apo-SAA1 to a concentration of 1mg/ml, cells were also treated 
with MilliQ water without SAA. 80μg/ml of SAA, the highest 
concentration used in this study, was prepared using 80μl of 1mg/ml SAA 
in 920μl of FBS free DMEM. Therefore, cells were also treated with mq 
80 which was prepared using 80μl of MilliQ water in 920μl of FBS free 
DMEM. The cells were incubated at 37oC, 5% CO2 for 24 h.  4 h before 
the end of incubation, 10μl of MTT solution (5mg/ml) (Molecular Probes, 
The Netherlands) was added into each well. At the end of 24 h, media 
were removed and 100μl of Dimethyl Sulfoxide (DMSO) was added into 
each well to solubilize the formazan crystals. The plate was shaken for 10 
min to ensure that all dark blue precipitate was dissolved before the plate 
was read at 570nm on a microplate reader (Tecan).  
 
 






Percentage cell viability =                                                                        x 100% 
 
average A570 nm of cells treated with 
various concentrations of SAA 
average A570 nm of control cells 
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2.9. Statistical method 
Mean ± standard deviation (SD) from three independent experiments (n=3) 
were calculated. Statistical significance of differences between means of 
test and control groups were analyzed by the Student’s t-test. A p-value of 




























3.1.1. Regulation of genes involved in atherosclerosis 
Quantitative real-time PCR was carried out to detect for regulation of 
target genes which are known to play important roles in atherosclerosis 
following SAA treatment. RAW264.7 seeded in 6 well-plates were 
treated with either FBS free DMEM, 40μg/ml or 80μg/ml of SAA for 1 
h, 3 h, 6 h or 24 h. After the appropriate time-points, RNA was 
extracted and real-time PCR was carried out to look out for any target 
gene regulation following SAA treatment.  
 
3.1.1.1. Genes involved in initiation of atherosclerosis 
Following exposure to SAA, significant regulation could be 
detected in targets which play important roles in the initiation of 
atherosclerosis, in particular ICAM-1 and MCP-1 (Figure 1 and 
Figure 2 respectively).  
Despite significant induction at 1 h, 3 h and 6 h, the greatest 
elevation of ICAM-1 was detected at 1 h following SAA treatment. 
As shown in Figure 1, the amount of ICAM-1 increased by up to 
4.0 fold and 4.7 fold after being treated with 40μg/ml and 80μg/ml 
of SAA respectively for an hour. 
The most significant induction of MCP-1 was detected at 6 h of 
exposure to SAA. Figure 2 shows that MCP-1 was up-regulated by 
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up to 5.5 fold and 26.2 fold after being exposed to 40μg/ml and 




Figure 1: Real-Time PCR analysis of ICAM-1 expression from control and SAA 
treated RAW264.7. RAW264.7 were treated with 40μg/ml or 80μg/ml of SAA for 1 
h, 3 h, 6 h or 24 h. **p<0.01 and *p<0.05 indicates statistical significant differences 
between SAA treated and control groups. Total cellular RNA was extracted using 
RNeasy Mini Kit (Qiagen) and Real-Time PCR was performed using LightCycler 480 
system (Roche). GAPDH was used as an endogenous control to normalize each target 
sample. The threshold cycle (CT) was determined by the accompanied software 
(Roche). A relative quantitative document was generated for analysis. Error bars 
































Figure 2: Real-Time PCR analysis of MCP-1 expression from control and SAA 
treated RAW264.7. RAW264.7 were treated with 40μg/ml or 80μg/ml of SAA for 1 
h, 3 h, 6 h or 24 h. **p<0.01 and *p<0.05 indicates statistical significant differences 
between SAA treated and control groups. Total cellular RNA was extracted using 
RNeasy Mini Kit (Qiagen) and Real-Time PCR was performed using LightCycler 480 
system (Roche). GAPDH was used as an endogenous control to normalize each target 
sample. The threshold cycle (CT) was determined by the accompanied software 
(Roche). A relative quantitative document was generated for analysis. Error bars 










































3.1.1.2. Genes involved in progression of atherosclerosis 
Similarly, significant regulation could be detected in targets which 
play important roles in the progression of atherosclerosis following 
SAA treatment.  
As shown in Figure 3 and Figure 4 respectively, MMP-9 was most 
significantly up-regulated at 6 h while TF was most significantly 
induced at 1 h following exposure to SAA. After being treated with 
40μg/ml and 80μg/ml of SAA for 6 h, MMP-9 level increased by 
as much as 28.7 fold and 53.5 fold respectively. TF level increased 
by up to 13.8 fold and 37.7 fold at 1 h following exposure to 








Figure 3: Real-Time PCR analysis of MMP-9 expression from control and SAA 
treated RAW264.7. RAW264.7 were treated with 40μg/ml or 80μg/ml of SAA for 1 
h, 3 h, 6 h or 24 h. **p<0.01 indicates statistical significant differences between SAA 
treated and control groups. Total cellular RNA was extracted using RNeasy Mini Kit 
(Qiagen) and Real-Time PCR was performed using LightCycler 480 system (Roche). 
GAPDH was used as an endogenous control to normalize each target sample. The 
threshold cycle (CT) was determined by the accompanied software (Roche). A 
relative quantitative document was generated for analysis. Error bars represent 

































Figure 4: Real-Time PCR analysis of TF expression from control and SAA 
treated RAW264.7. RAW264.7 were treated with 40μg/ml or 80μg/ml of SAA for 1 
h, 3 h, 6 h or 24 h. **p<0.01 and *p<0.05 indicates statistical significant differences 
between SAA treated and control groups. Total cellular RNA was extracted using 
RNeasy Mini Kit (Qiagen) and Real-Time PCR was performed using LightCycler 480 
system (Roche). GAPDH was used as an endogenous control to normalize each target 
sample. The threshold cycle (CT) was determined by the accompanied software 
(Roche). A relative quantitative document was generated for analysis. Error bars 






































3.1.2.  NFκB activation inhibited through Bay11-7082 
As ICAM-1, MCP-1, MMP-9 and TF are known to be downstream 
targets of NFκB, we proceeded to determine if SAA was up-regulating 
these targets through NFκB with the use of Bay11-7082, an irreversible 
inhibitor of NFκB. As mentioned previously, NFκB is kept inactive 
when bound to IκB. IκB degradation would therefore, allow NFκB 
activation. Bay11-7082 functions by inhibiting IκB degradation, 
preventing the activation of NFκB.   
In order to first determine the effect of SAA on NFκB activity, cells 
were seeded in 6 well-plates and treated with FBS free DMEM or SAA 
at 80μg/ml for 5 min, 15 min or 30 min.  After which, protein was 
extracted and western blot was carried out to look out for changes in 
IκB level (Figure 5). 
To prove the ability of Bay11-7082 to inhibit NFκB activity following 
SAA treatment, cells seeded in 6 well-plates were pretreated with 
Bay11-7082 at 10μM for an hour before they were treated with FBS 
free DMEM or SAA at 80μg/ml for 5 min, 15 min or 30 min.  
Similarly, protein was then extracted and western blot was carried out 
to look out for changes in IκB level (Figure 5). 
As shown in Figure 5, under normal conditions, IκB underwent 
degradation within 30 min following SAA treatment. Signs of IκB 
degradation could be detected as early as 15 min following exposure to 
SAA. However, when pretreated with Bay11-7082, IκB degradation 
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following SAA treatment was inhibited, as deduced by the absence of 




                            
  
 
Figure 5: Western blot of IκB from control and SAA treated 
RAW264.7 with or without Bay11-7082 pretreatment. RAW264.7 
were pretreated with or without 10μM Bay11-7082 for 1 h before 
treatment with 80μg/ml of SAA for 5 m, 15 m or 30 m. Protein samples 
were immunoblotted with anti-IκB and anti-GAPDH antibodies. Blots 
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3.1.3. Involvement of NFκB in up-regulation of genes 
involved in atherosclerosis 
To determine if NFκB played a role in the regulation of the four 
mentioned targets, cells were first pretreated with 10μM Bay11-7082 
for an hour to ensure complete inhibition of NFκB activity before they 
were treated with FBS free DMEM or SAA at 40μg/ml or 80μg/ml for 
1 h, 3 h or 6 h. After which, RNA was extracted and quantitative real-
time PCR was carried out to detect for changes in the level of the four 
target genes following SAA treatment when NFκB activity was 
inhibited.  
 
3.1.3.1. Genes involved in initiation of atherosclerosis 
Following SAA treatment, induction of ICAM-1 and MCP-1 were 
significantly suppressed when NFκB was inhibited as compared to 
when NFκB was not inhibited (Figure 6 and Figure 7 respectively).  
As shown in Figure 6, the 4.0 fold and 4.7 fold increase in ICAM-1 
level at 1 h following treatment with 40μg/ml and 80μg/ml of SAA 
respectively was reduced to just 1.2 fold and 1.3 fold when NFκB 
was inhibited.  
Similarly from Figure 7, MCP-1 transcript level increased by up to 
5.5 fold and 26.2 fold when exposed to 40μg/ml and 80μg/ml of 
SAA respectively for 6 h without NFκB inhibition. These values 
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were significantly reduced to 1.3 fold and 1.7 fold respectively 




Figure 6: Real-Time PCR analysis of ICAM-1 expression from control and SAA 
treated RAW264.7 with or without Bay11-7082 pretreatment. RAW264.7 were 
pretreated with or without 10μM Bay11-7082 for 1 h before treatment with 40μg/ml 
or 80μg/ml of SAA for 1 h, 3 h or 6 h. **p<0.01 and *p<0.05 indicates statistical 
significant differences between Bay11-7082 pretreated and non-pretreated groups. 
Total cellular RNA was extracted using RNeasy Mini Kit (Qiagen) and Real-Time 
PCR was performed using LightCycler 480 system (Roche). GAPDH was used as an 
endogenous control to normalize each target sample. The threshold cycle (CT) was 
determined by the accompanied software (Roche). A relative quantitative document 
was generated for analysis. Error bars represent standard deviations (n=3). 
  
 






























Figure 7: Real-Time PCR analysis of MCP-1 expression from control and SAA 
treated RAW264.7 with or without Bay11-7082 pretreatment. RAW264.7 were 
pretreated with or without 10μM Bay11-7082 for 1 h before treatment with 40μg/ml 
or 80μg/ml of SAA for 1 h, 3 h or 6 h. **p<0.01 and *p<0.05 indicates statistical 
significant differences between Bay11-7082 pretreated and non-pretreated groups. 
Total cellular RNA was extracted using RNeasy Mini Kit (Qiagen) and Real-Time 
PCR was performed using LightCycler 480 system (Roche). GAPDH was used as an 
endogenous control to normalize each target sample. The threshold cycle (CT) was 
determined by the accompanied software (Roche). A relative quantitative document 












































3.1.3.2. Genes involved in progression of atherosclerosis 
Likewise, induction of MMP-9 and TF following SAA treatment 
were significantly suppressed with NFκB inhibition as compared to 
when NFκB was not inhibted (Figure 8 and Figure 9 respectively).  
From Figure 8, significant suppression could be seen at 6 h 
whereby a 28.7 fold and 53.5 fold increase in MMP-9 level 
following exposure to 40μg/ml and 80μg/ml of SAA respectively 
without NFκB inhibition was reduced to 3.2 fold and 8.1 fold when 
NFκB activity was inhibited. 
Similarly, from Figure 9, the 13.8 fold and 37.7 fold increase in TF 
level at 1 h following treatment with 40μg/ml and 80μg/ml of SAA 
respectively was significantly reduced to just 1.7 fold and 2.5 fold 











Figure 8: Real-Time PCR analysis of MMP-9 expression from control and SAA 
treated RAW264.7 with or without Bay11-7082 pretreatment. RAW264.7 were 
pretreated with or without 10μM Bay11-7082 for 1 h before treatment with 40μg/ml 
or 80μg/ml of SAA for 1 h, 3 h or 6 h. **p<0.01 indicates statistical significant 
differences between Bay11-7082 pretreated and non-pretreated groups. Total cellular 
RNA was extracted using RNeasy Mini Kit (Qiagen) and Real-Time PCR was 
performed using LightCycler 480 system (Roche). GAPDH was used as an 
endogenous control to normalize each target sample. The threshold cycle (CT) was 
determined by the accompanied software (Roche). A relative quantitative document 





































Figure 9: Real-Time PCR analysis of TF expression from control and SAA 
treated RAW264.7 with or without Bay11-7082 pretreatment. RAW264.7 were 
pretreated with or without 10μM Bay11-7082 for 1 h before treatment with 40μg/ml 
or 80μg/ml of SAA for 1 h, 3 h or 6 h. **p<0.01 and *p<0.05 indicates statistical 
significant differences between Bay11-7082 pretreated and non-pretreated groups. 
Total cellular RNA was extracted using RNeasy Mini Kit (Qiagen) and Real-Time 
PCR was performed using LightCycler 480 system (Roche). GAPDH was used as an 
endogenous control to normalize each target sample. The threshold cycle (CT) was 
determined by the accompanied software (Roche). A relative quantitative document 









































3.1.4. Involvement of TNFα in NFκB regulation by SAA 
In addition to ICAM-1, MCP-1, MMP-9 and TF, SAA was also found 
to significantly up-regulate TNFα. As shown in Figure 10, when 
exposed to 40μg/ml and 80μg/ml of SAA, TNFα level increased by up 
to 10.1 fold and 12.5 fold respectively at 1 h. These values 
subsequently decreased to 1.7 fold and 2.4 fold by 24 h.  
 
 
Figure 10: Real-Time PCR analysis of TNFα expression from control and SAA 
treated RAW264.7. RAW264.7 were treated with 40μg/ml or 80μg/ml of SAA for 1 
h, 3 h, 6 h or 24 h. **p<0.01 and *p<0.05 indicates statistical significant differences 
between SAA treated and control groups. Total cellular RNA was extracted using 
RNeasy Mini Kit (Qiagen) and Real-Time PCR was performed using LightCycler 480 
system (Roche). GAPDH was used as an endogenous control to normalize each target 
sample. The threshold cycle (CT) was determined by the accompanied software 
(Roche). A relative quantitative document was generated for analysis. Error bars 



































To determine if induction of TNFα was also mediated through NFκB, 
cells were pretreated with 10μM Bay11-7082 for 1 h before they were 
exposed to SAA at 40μg/ml or 80μg/ml for 1 h, 3 h or 6 h.  
As shown in Figure 11, following SAA treatment, inhibition of NFκB 
resulted in a significant change in the level of TNFα at 6 h as compared 
to when NFκB was not inhibited. At 6 h, there was only a slight 
suppression in the induction of TNFα following exposure to 80μg/ml 
of SAA with inhibition of NFκB as compared to when NFκB was not 
inhibited. Without NFκB inhibition, exposure to 80μg/ml of SAA 
increased TNFα by approximately 7 fold at 6 h. This level decreased to 
approximately 4 fold with Bay11-7082 pre-treatment under the same 









Figure 11: Real-Time PCR analysis of TNFα expression from control and SAA 
treated RAW264.7 with or without Bay11-7082 pretreatment. RAW264.7 were 
pretreated with or without 10μM Bay11-7082 for 1 h before treatment with 40μg/ml 
or 80μg/ml of SAA for 1 h, 3 h or 6 h. *p<0.05 indicates statistical significant 
differences between Bay11-7082 pretreated and non-pretreated groups. Total cellular 
RNA was extracted using RNeasy Mini Kit (Qiagen) and Real-Time PCR was 
performed using LightCycler 480 system (Roche). GAPDH was used as an 
endogenous control to normalize each target sample. The threshold cycle (CT) was 
determined by the accompanied software (Roche). A relative quantitative document 










































3.2.1. Role of SAA in the initiation of atherosclerosis 
To determine whether SAA has an effect on the initiation of 
atherosclerosis, quantitative real-time PCR was carried out to detect for 
regulation of target genes which are known to play important roles in 
initiating atherosclerosis.  
SAA was found to significantly induce ICAM-1 in RAW264.7 as 
shown in Figure 1. ICAM-1 encodes for intercellular adhesion 
molecules which are found on cell membranes. The increased 
expression of such molecules on endothelial cells would help in 
facilitating the recruitment and adhesion of macrophages to damaged 
sites through improved interaction between macrophages and 
endothelial cells surrounding these lesion sites, aiding in the initiation 
of atherosclerosis. Fatty streaks which are seen as the earliest form of 
lesion showed evidences of macrophage accumulation (Palinski and 
Napoli, 2002). Similar to what we have found, the ability of SAA to 
induce ICAM-1 in fibroblast-like synoviocytes was reported by Mullan 
and his team in a study to determine the effects of SAA on Rheumatoid 
Arthritis (Mullan et al., 2006). Although the ability of SAA to induce 
ICAM-1 expression on endothelial cells was not tested in this study, 
the competency of SAA to induce ICAM-1 on macrophages may 
demonstrate the potential of SAA in triggering atherosclerosis.  
MCP-1 is a chemoattractant which attracts monocytes into the intima 
where the latter would differentiate into macrophages. These 
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macrophages would then phagocytose modified lipoproteins, forming 
foam cells which are seen as hallmark of early stage atherosclerosis 
(Libby et al., 2010). From the results shown in Figure 2, MCP-1 of 
RAW264.7 was found to be very significantly induced by SAA at both 
40μg/ml and 80μg/ml. The up-regulation of MCP-1 by SAA was also 
mentioned by Song and his team using peripheral blood mononuclear 
cells (PBMC) and human THP-1 monocytes (Song et al., 2009). The 
stimulation of MCP-1 in RAW264.7 by SAA provides an indication of 
the ability of SAA to induce MCP-1 expression in monocytes, 
confirming the findings of Song and his team. Given the importance of 
MCP-1 in initiating atherosclerosis, the ability of SAA to induce MCP-
1 in RAW264.7 provided an insight on the capability of SAA to initiate 
atherosclerosis.  
Although western blot was carried out to detect for the up-regulation of 
both ICAM-1 and MCP-1, the proteins could not be detected.  
 
3.2.2. Role of SAA in the progression of atherosclerosis 
In addition to its ability to initiate atherosclerosis, SAA was also tested 
for its ability to promote atherosclerotic progression. Similarly, 
quantitative real-time PCR was carried out to determine the effects of 
SAA on target genes which are known to play important roles in 
assisting atherosclerotic progression. 
MMPs are a family of zinc-dependent endopeptidases. They are 
capable of breaking down extracellular matrix, hence promoting 
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fibrous cap thinning, plaque destabilization and eventually plaque 
rupture (Zhao et al., 2009; Halvorsen et al., 2008; Monaco and 
Paleolog, 2004). As mentioned earlier, MMP-9 in particular, has been 
associated with atherosclerosis and is even seen as a marker of unstable 
plaque (Kunte et al., 2008). Other than the strong association between 
elevated MMP-9 level and increased risk of fatal coronary event as 
reported by Blankenberg and his team (Blankenberg et al., 2003), 
MMP-9 level was also recently shown to be significantly induced in 
the heart tissue of a patient who died of myocardial rupture (Van den 
Borne et al., 2009).   
As shown in Figure 3, SAA was found to induce MMP-9 level by up to 
28.7 fold and 53.5 fold when cells were treated with 40μg/ml and 
80μg/ml of SAA respectively for 6 h. This result can be justified by an 
earlier study where Lee and team also found the ability of SAA to 
induce MMP-9 expression in Human THP-1 monocytes (Lee et al., 
2005). However, our study done using macrophages instead of 
monocytes may provide a better indication of the situation within a 
lesion since macrophages instead of monocytes form the main core of 
atherosclerotic plaques (Tabas, 2004). The ability of SAA to 
significantly induce MMP-9 emphasizes the important role of SAA in 
atherosclerotic progression.  
From Figure 4, effect of SAA on TF was also observed. SAA at 
concentrations of 40μg/ml and 80μg/ml could induce TF gene 
expression by up to 13.8 fold and 37.7 fold respectively within an hour 
following exposure. TF is known for its role in the activation of the 
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coagulation cascade (Monaco and Paleolog, 2004). In the event of a 
rupture, elevated TF level would promote coagulation, leading to 
thrombosis which may eventually result in a fatal outcome following 
myocardial infarction. The ability of SAA to induce TF expression in 
PBMC was previously reported by Cai and his team (Cai et al., 2007). 
With its control over TF, SAA has an effect on the coagulation cascade 
and thus, contributes to the progression of atherosclerosis.  
Similarly, western blot was carried out to detect for the up-regulation 
of both MMP-9 and TF at the protein level. However, both proteins 
could not be detected.  
 
3.2.3. Involvement of NFκB in up-regulation of ICAM-1, MCP-1, 
MMP-9 and TF by SAA 
The four targets mentioned above, namely ICAM-1, MCP-1, MMP-9 
and TF, are known downstream targets of NFκB (Sprague and Khalil, 
2009; Boyle, 2005). To determine if effect of SAA on these targets was 
mediated through NFκB, the level of IκB following SAA treatment 
was probed using western blot.  
As previously mentioned, IκB is an inhibitor of NFκB which keeps 
NFκB inactive under normal conditions. When bound, IκB blocks the 
nuclear localization sequence of NFκB, preventing NFκB from gaining 
entry into the nucleus, inhibiting NFκB activation. The presence of IκB 
would therefore, indicate the inhibition of NFκB as seen under normal 
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conditions. IκB degradation, on the other hand, would denote NFκB 
activation.  
From Figure 5, we see that RAW264.7, when treated with 80μg/ml of 
SAA for increasing time-durations, showed signs of IκB degradation, 
indicating NFκB activation following treatment. This finding is similar 
to what was found by He and his team. Similar to our observations, He 
and his team found the ability of SAA to stimulate NFκB in human 
neutrophils via an electrophoretic mobility shift assay (EMSA) (He et 
al., 2003). Figure 5 shows that SAA was able to activate NFκB in 
RAW264.7 through IκB degradation. SAA could have induced NFκB 
activation through the stimulation of TNFα and cytokines. IKK, when 
activated by TNFα and cytokines, would phosphorylate IκB, resulting 
in its degradation. However, from this alone, we still could not 
conclude if the effect of SAA on the four mentioned targets was 
mediated through NFκB.  
In order to determine if regulation of the four targets were mediated 
through NFκB, Bay11-7082 was employed to inhibit NFκB activity 
before the cells were treated with SAA of various concentrations for 
various time-durations. Bay11-7082 is an irreversible inhibitor of 
NFκB as it inhibits IκB phosphorylation. IκB when phosphorylated, 
gets ubiquitinated and subsequently, degraded. The presence of Bay11-
7082 therefore, prevents IκB degradation and in doing so, keeps NFκB 
inhibited. The efficiency of Bay11-7082 in keeping NFκB inhibited 
could be attested from Figure 5. As mentioned, treatment of 
RAW264.7 with 80μg/ml of SAA resulted in IκB degradation, 
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indicating NFκB activation following SAA treatment. RAW264.7 
when pretreated with Bay11-7082 showed constant IκB level following 
SAA treatment, indicating the success of Bay11-7082 in inhibiting 
NFκB activation.  
When pretreated with Bay11-7082, induction of ICAM-1, MCP-1, 
MMP-9 and TF by SAA were significantly suppressed as compared to 
what were previously observed when NFκB was not inhibited (Figure 
6, 7, 8 and 9 respectively). In fact, all targets showed very significant 
suppression in regulation following SAA treatment when NFκB was 
inhibited. TF, for instance, showed a reduction in fold change, from 
37.7 fold to 2.5 fold, following treatment with 80μg/ml of SAA for 1 h 
when NFκB was inhibited. From these, we could infer that the 
induction of ICAM-1, MCP-1, MMP-9 and TF by SAA relied on the 
presence of NFκB activity as the induction of these targets by SAA 
were suppressed in the presence of irreversible NFκB inhibitor Bay11-
7082. 
With the knowledge that SAA promotes atherosclerosis through the 
NFκB pathway, one potential way to prevent SAA-induced 
atherosclerosis would be through the inhibition of NFκB. However, 
given the role of NFκB in numerous vital functions, this strategy would 
not be possible. One viable way to prevent SAA-induced 
atherosclerosis would be through the selective inhibition of 
atherosclerosis-specific targets found downstream of NFκB. Down-
regulation of SAA-inducible proinflammatory targets such as MMP-9 
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by therapeutic target may help in the prevention of SAA-induced 
atherosclerosis.  
 
3.2.4. Association of TNFα with SAA-induced NFκB 
regulation 
In addition to the above four mentioned pro-atherosclerotic targets, 
TNFα was also found to be induced following SAA treatment (Figure 
10). A study done by Lee and team also reported the ability of SAA to 
induce TNFα in human monocytes (Lee et al., 2006). As a 
proinflammatory cytokine, TNFα has been linked to atherosclerosis 
(Kutuk and Basaga, 2003). Research has shown that TNFα is able to 
activate NFκB (Monaco and Paleolog, 2004). However, there are also 
reports suggesting that NFκB could regulate TNFα (Baker et al., 2011).  
To determine if TNFα induction following SAA treatment was due to 
NFκB, we inhibited NFκB as was previously done using Bay11-7082 
before cells were treated with SAA of various concentrations for 
various time-durations. This inhibition in NFκB did not bring about 
significant suppression of TNFα induction at the 1 h and 3 h time-
points following SAA treatment as compared to when NFκB was not 
inhibited (Figure 11). At the 6 h time-point, the level of TNFα 
induction observed when NFκB was inhibited was just significantly 
different from the level of TNFα induction observed when NFκB was 
not inhibited with a p-value of 0.044. As this significance came at a 
later time-point, we speculate that TNFα up-regulation following SAA 
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treatment, in this case, was not mediated through NFκB. Instead, SAA 
has a direct effect on TNFα induction.  
It is known that NFκB, when activated, could activate TNFα as a 
feedback mechanism (Shukla et al., 2011). The inhibition of NFκB in 
the presence of Bay11-7082 would have eliminated the feedback 
activation of TNFα by NFκB. This could explain for the slight 
reduction in TNFα induction, from a 7 fold increase to a 4 fold increase, 
at the 6 h time-point following SAA treatment when NFκB was 
inhibited. We therefore, speculate that SAA is able to up-regulate 
TNFα through an NFκB independent pathway, as TNFα induction was 
not much affected by NFκB inhibition. Instead, the direct activation of 
TNFα by SAA could be the mechanism through which SAA activated 
NFκB in RAW264.7 as suggested previously.   
As NFκB is able to activate TNFα to create a positive feedback loop, 
the ability of SAA to regulate both TNFα and NFκB would result in a 
vicious cycle of inflammation. With the ability of SAA to induce 
ICAM-1, MCP-1, MMP-9 and TF through NFκB as shown previously, 
the positive feedback loop would result in a prolonged inflammatory 
reaction which would further enhance atherosclerosis, emphasizing the 
























4.1.1. Reduction in cell viability 
In order to determine if SAA is able to reduce cell viability and if so, 
the concentration of SAA to be studied, MTT assay was carried out. 
Approximately 5 x 103 cells were seeded into each well of a 96-well 
plate. The cells were incubated with either FBS free media or various 
concentrations of SAA (5-80μg/ml) for 24 h. Results (n=3) obtained 
from this assay were plotted into a graph (Figure 12).  
 
As can been seen from the graph obtained, SAA reduced cell viability 
in a dose dependent manner, with significant reduction in cell viability 
being observed following treatment with 40μg/ml and 80μg/ml of 
SAA. From the graph, 40μg/ml of SAA reduced cell viability to 79.6% 











Figure 12: MTT assay of RAW264.7 treated with control or SAA of various 
concentrations (5-80μg/ml) (n=3). RAW264.7 were treated with 100μl of the 
various media for 24 h. For mq 80, MilliQ water was used in place of SAA **p<0.01 
indicates statistical significant differences between SAA treated and control groups. 
10μl of MTT solution (5mg/ml) was added into each well 4 h before the end of 
incubation. At the end of incubation, all media were removed and 100μl of DMSO 
was added into each well. Percentage cell viability was quantitated using the 









































4.1.2. Regulation of apoptotic genes 
Quantitative real-time PCR was then carried out to look out for 
regulation of apoptotic genes following SAA treatment. RNA 
extracted from cells treated with 40μg/ml or 80μg/ml of SAA for 
various time-durations when measured against RNA extracted from 
cells treated with FBS free media showed significant regulation in Fas 
and Bcl-2 expression as plotted in Figure 13 and Figure 14 
respectively. 
 
Figure 13 shows that Fas was up-regulated at all time-points, with the 
most significant up-regulation of approximately 10.2 fold and 13.2 
fold being recorded at 3 h after exposure to 40μg/ml and 80μg/ml of 
SAA respectively.  
 
Bcl-2, on the other hand, was significantly down-regulated at the 3 h 
and 24 h time-points. As shown in Figure 14, transcript level of Bcl-2 












Figure 13: Real-Time PCR analysis of Fas expression from control and SAA 
treated RAW264.7. RAW264.7 were treated with 40μg/ml or 80μg/ml of SAA for 1 
h, 3 h, 6 h or 24 h. **p<0.01 and *p<0.05 indicates statistical significant differences 
between SAA treated and control groups. Total cellular RNA was extracted using 
RNeasy Mini Kit (Qiagen) and Real-Time PCR was performed using LightCycler 480 
system (Roche). GAPDH was used as an endogenous control to normalize each target 
sample. The threshold cycle (CT) was determined by the accompanied software 
(Roche). A relative quantitative document was generated for analysis. Error bars 










































Figure 14: Real-Time PCR analysis of Bcl-2 expression from control and SAA 
treated RAW264.7. RAW264.7 were treated with 40μg/ml or 80μg/ml of SAA for 1 
h, 3 h, 6 h or 24 h. **p<0.01 and *p<0.05 indicates statistical significant differences 
between SAA treated and control groups. Total cellular RNA was extracted using 
RNeasy Mini Kit (Qiagen) and Real-Time PCR was performed using LightCycler 480 
system (Roche). GAPDH was used as an endogenous control to normalize each target 
sample. The threshold cycle (CT) was determined by the accompanied software 
(Roche). A relative quantitative document was generated for analysis. Error bars 











































4.1.3. Regulation of apoptotic proteins 
Western blot was also carried out to determine if apoptosis was indeed 
occurring through the detection of changes in the level of apoptotic 
proteins. The level of caspase 3, an executioner caspase which plays 
an important role in apoptosis, was being determined after cells were 
treated with 80μg/ml of SAA for various time-durations. As can be 
observed from Figure 15, protein level of uncleaved caspase 3 was 
reduced with increasing time-point, with the most significant down-
regulation being observed at 6 h following SAA exposure. 
 
Protein level of PARP, a downstream target of activated caspase 3, 
was also determined through western blot after cells were treated with 
80μg/ml of SAA for various time-durations. Similar to what was 
observed for uncleaved caspase 3, protein level of uncleaved PARP 
decreased with increasing time-point, with the most significant 





                                  
 
 
Figure 15: Western blot of caspase 3 from control and SAA treated 
RAW264.7. RAW264.7 were incubated with 80μg/ml of SAA for 1 h, 3 h or 
6 h. Protein samples were immunoblotted with anti-caspase 3 and anti-












                                    
 
Figure 16: Western blot of PARP from control and SAA treated 
RAW264.7. RAW264.7 were incubated with 80μg/ml of SAA for 3 h, 6 h or 
24 h. Protein samples were immunoblotted with anti-PARP and anti-






With these changes being observed in downstream apoptotic markers, 
western blot was subsequently carried out on apoptotic proteins which 
are found just upstream of caspase 3, namely caspase 8 and caspase 9. 
However, as can be seen from Figure 17, changes were not observed 




                                    
 
 
Figure 17: Western blot of caspase 8 and caspase 9 from control and 
SAA treated RAW264.7. RAW264.7 were incubated with 80μg/ml of SAA 
for 1 h, 3 h or 6 h. Protein samples were immunoblotted with anti-caspase 8 
and anti-caspase 9 and anti-GAPDH antibodies. Blots shown are 
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4.1.4. Involvement of NFκB in apoptosis 
Earlier, SAA was shown to be able to activate NFκB (Figure 5). As 
NFκB is usually known for promoting cell survival, we proceeded to 
determine if SAA could induce a more pronounced apoptotic effect 
when NFκB was inhibited. Thus, cells were pretreated with 10μM 
Bay11-7082 for an hour to inhibit NFκB activity before they were 
treated with 80μg/ml of SAA for various time-durations. Western blot 
was then carried out to detect for changes in the protein level of 
apoptotic targets. 
 
However, as shown in Figure 18, inhibition of NFκB resulted in no 
changes in the protein level of PARP (uncleaved) and caspase 3 
(uncleaved). Similarly, no significant changes could be observed in 
the protein level of uncleaved caspase 8 and caspase 9 following SAA 















                                                    
Figure 18: Western blot of PARP, caspase 3, caspase 8 and caspase 9 
from control and SAA treated RAW264.7 with Bay11-7082 
pretreatment. RAW264.7 were pretreated with 10μM Bay11-7082 for 1 h 
before treatment with FBS free DMEM (Control) or 80μg/ml of SAA for 1 
h, 3 h or 6 h. Protein samples were immunoblotted with anti-PARP, anti-
caspase 3, anti-caspase 8, anti-caspase 9 and anti-GAPDH antibodies. 
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4.1.5. Mechanism of apoptosis 
In order to elucidate the mechanism through which SAA induced 
apoptosis, we examined possible targets which might have played a 
role in regulating SAA-induced apoptosis.  
  
4.1.5.1. Extrinsic apoptotic pathway 
As one of the main apoptotic pathways, the extrinsic pathway is a 
possible mechanism through which apoptosis occurred. 
 
4.1.5.1.1. Fas 
When pre-treated with Bay11-7082, SAA-treated RAW264.7 
showed a decrease in apoptotic activity as shown by the lack of 
apoptotic protein cleavage (Figure 18). To determine if this lack 
of apoptotic activity was due to a reduction in Fas up-regulation 
following NFκB inhibition, quantitative real-time PCR was 
carried out on SAA-exposed RAW264.7 which had been 
pretreated with Bay11-7082.  
Compared to the induction of Fas when NFκB was not inhibited, 
up-regulation of Fas by SAA was significantly suppressed at 1 h 
and 3 h following Bay11-7082 pre-treatment. However, 





Figure 19: Real-Time PCR analysis of Fas expression from control and SAA 
treated RAW264.7 with or without Bay11-7082 pretreatment. RAW264.7 were 
pretreated with or without 10μM Bay11-7082 for 1 h before treatment with 40μg/ml 
or 80μg/ml of SAA for 1 h, 3 h or 6 h. **p<0.01 and *p<0.05 indicates statistical 
significant differences between Bay11-7082 pretreated and non-pretreated groups. 
Total cellular RNA was extracted using RNeasy Mini Kit (Qiagen) and Real-Time 
PCR was performed using LightCycler 480 system (Roche). GAPDH was used as an 
endogenous control to normalize each target sample. The threshold cycle (CT) was 
determined by the accompanied software (Roche). A relative quantitative document 




A20, a downstream target of NFκB, recently gained interest due 
to its anti-apoptotic properties. Having shown the ability of SAA 
to induce NFκB (Figure 5), we next determined the effect of 
SAA on A20. Following SAA treatment, quantitative real-time 
PCR and western blot were carried out to detect for regulation of 


































Cells treated with various concentrations of SAA for various 
time-durations showed significant induction of A20 at both 
transcript and protein level (Figure 20 and Figure 21 
respectively). 
From Figure 20, A20 transcript showed a dramatic increase of 
approximately 46.7 fold within the first hour of being exposed to 
80μg/ml of SAA. This induction subsequently decreased to less 
than 5.0 fold by 3 h. At 24 h following SAA exposure, only a 1.5 
fold increase in A20 level was observed.   
The induction of A20 expression following SAA treatment was 
further confirmed by a corresponding increase in A20 protein as 
observed in Figure 21. Similar to the quantitative real-time PCR 
results shown in Figure 20, the increase in A20 protein was more 
significant at shorter time-points. This increase in protein level 







Figure 20: Real-Time PCR analysis of A20 expression from control and SAA 
treated RAW264.7. RAW264.7 were treated with 40μg/ml or 80μg/ml of SAA for 1 
h, 3 h, 6 h or 24 h. **p<0.01 indicates statistical significant differences between SAA 
treated and control groups. Total cellular RNA was extracted using RNeasy Mini Kit 
(Qiagen) and Real-Time PCR was performed using LightCycler 480 system (Roche). 
GAPDH was used as an endogenous control to normalize each target sample. The 
threshold cycle (CT) was determined by the accompanied software (Roche). A 
relative quantitative document was generated for analysis. Error bars represent 





                                    
 
Figure 21: Western blot of A20 from control and SAA treated 
RAW264.7. RAW264.7 were incubated with 80μg/ml of SAA for 1 h, 3 h 
or 6 h. Protein samples were immunoblotted with anti-A20 and anti-
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In order to determine if A20 induction by SAA was affected by 
NFκB activity, cells were first pretreated with 10μM Bay11-7082 
for 1 h before they were exposed to various concentrations of 
SAA for various time-durations. Quantitative real-time PCR and 
western blot were then carried out to detect for regulation of A20 
at both transcript and protein level respectively.   
Pretreatment of cells with Bay11-7082 suppressed SAA-induced 
A20 induction significantly, especially at the first hour whereby 
increase in A20 transcript level was reduced from 46.7 fold to 5.7 
fold after being treated with 80μg/ml of SAA (Figure 22).  
Bay11-7082 pretreated cells, when exposed to 80μg/ml of SAA 
for 6 h, showed only a 2.5 fold increase in A20 transcript level. 
This suppression of A20 transcript, following SAA exposure 
with Bay11-7082 pretreatment, was also reflected at the protein 
level as shown in Figure 23. Compared to Figure 21, this up-
regulation of A20 following SAA treatment was much less 




Figure 22: Real-Time PCR analysis of A20 expression from control and SAA 
treated RAW264.7 with or without Bay11-7082 pretreatment. RAW264.7 were 
pretreated with or without 10μM Bay11-7082 for 1 h before treatment with 40μg/ml 
or 80μg/ml of SAA for 1 h, 3 h or 6 h. **p<0.01 indicates statistical significant 
differences between Bay11-7082 pretreated and non-pretreated groups. Total cellular 
RNA was extracted using RNeasy Mini Kit (Qiagen) and Real-Time PCR was 
performed using LightCycler 480 system (Roche). GAPDH was used as an 
endogenous control to normalize each target sample. The threshold cycle (CT) was 
determined by the accompanied software (Roche). A relative quantitative document 
was generated for analysis. Error bars represent standard deviations (n=3). 
 
 
   
                                     
 
Figure 23: Western blot of A20 from control and SAA treated 
RAW264.7 with Bay11-7082 pretreatment. RAW264.7 were pretreated 
with 10μM Bay11-7082 for 1 h before treatment with FBS free DMEM 
(Control) or 80μg/ml of SAA for 1 h, 3 h or 6 h. Protein samples were 
immunoblotted with anti-A20 and anti-GAPDH antibodies. Blots shown 
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4.1.5.2. Intrinsic apoptotic pathway 
As one of the main apoptotic pathways, the intrinsic pathway is 
also a possible mechanism through which apoptosis occurred. 
 
4.1.5.2.1. Bcl-2 
As mentioned earlier, cells when exposed to SAA showed a 
reduction in the Bcl-2 transcript level (Figure 14). This decrease 
in Bcl-2 level was further confirmed through western blot 
whereby a reduction in Bcl-2 protein level was similarly detected 
following exposure of cells to 80μg/ml of SAA for various time-
durations (Figure 24).  
 
 
                                     
 
Figure 24: Western blot of Bcl-2 from control and SAA treated 
RAW264.7. RAW264.7 were incubated with 80μg/ml of SAA for 1 h, 3 h 
or 6 h. Protein samples were immunoblotted with anti-Bcl-2 and anti-










       C                 1h                 3h                6h       
94 
 
However, when cells were pretreated with Bay11-7082 before 
they were exposed to SAA of various concentrations, the 
reduction in Bcl-2 transcript level that was previously observed 
at 3 h following SAA exposure was abolished as seen in Figure 
25. Bcl-2 transcript reduction following SAA exposure observed 
when NFκB was not inhibited returned to near baseline level 
when cells were pretreated with Bay11-7082 as quantified by 
real-time PCR.  
 
Western blot was also carried out on cells pretreated with 10μM 
Bay11-7082 for 1 h before they were exposed to 80μg/ml of 
SAA for various time-durations. As shown in Figure 26, 
pretreatment of cells with Bay11-7082 prior to SAA exposure 
eliminated the down-regulation of Bcl-2 protein level that was 
previously seen in Figure 24, confirming the quantitative real-







Figure 25: Real-Time PCR analysis of Bcl-2 expression from control and SAA 
treated RAW264.7 with or without Bay11-7082 pretreatment. RAW264.7 were 
pretreated with or without 10μM Bay11-7082 for 1 h before treatment with 40μg/ml 
or 80μg/ml of SAA for 1 h, 3 h or 6 h. **p<0.01 indicates statistical significant 
differences between Bay11-7082 pretreated and non-pretreated groups. Total cellular 
RNA was extracted using RNeasy Mini Kit (Qiagen) and Real-Time PCR was 
performed using LightCycler 480 system (Roche). GAPDH was used as an 
endogenous control to normalize each target sample. The threshold cycle (CT) was 
determined by the accompanied software (Roche). A relative quantitative document 




                                     
 
Figure 26: Western blot of Bcl-2 from control and SAA treated 
RAW264.7 with Bay11-7082 pretreatment. RAW264.7 were pretreated 
with 10μM Bay11-7082 for 1 h before treatment with FBS free DMEM 
(Control) or 80μg/ml of SAA for 1 h, 3 h or 6 h. Protein samples were 
immunoblotted with anti-Bcl-2 and anti-GAPDH antibodies. Blots shown 
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4.1.5.3. JNK activation 
Research in recent years has associated JNK activation with both 
extrinsic and intrinsic apoptotic pathway. To determine if JNK is 
involved in SAA-induced apoptosis, western blot was carried out to 
determine if JNK was activated following exposure to 80μg/ml of 
SAA, with or without Bay11-7082 pretreatment. 
As shown in Figure 27, following exposure to 80μg/ml of SAA 
without NFκB inhibition, JNK could not be activated as shown by 
the absence of phosphorylated JNK (p-JNK) protein at all time-
points. 
However, pretreatment of cells with Bay11-7082 before exposure 
to 80μg/ml of SAA allowed for the activation of JNK as shown by 
the presence of p-JNK at 5 min and 15 min of exposure to SAA 
(Figure 28).  p-JNK level subsequently decreased by 30 min of 
exposure to SAA. 
 
                                    
 
Figure 27: Western blot of p-JNK from control and SAA treated 
RAW264.7. RAW264.7 were incubated with 80μg/ml of SAA for 5 m, 15 
m or 30 m. Protein samples were immunoblotted with anti-phospho-JNK 













                                     
 
Figure 28: Western blot of p-JNK from control and SAA treated 
RAW264.7 with Bay11-7082 pretreatment. RAW264.7 were pretreated 
with 10μM Bay11-7082 for 1 h before treatment with FBS free DMEM 
(Control) or 80μg/ml of SAA for 5 m, 15 m or 30 m. Protein samples were 
immunoblotted with anti-phospho-JNK and anti-JNK antibodies. Blots 
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4.2.1. Effect of SAA on cell viability 
Apoptosis plays an important role in the progression of atherosclerosis, 
especially through its role in disrupting plaque stability. A simple 
viability assay was first carried out to determine whether SAA has any 
effect on cell viability. In this case, MTT assay was carried out to 
quantify percentage of viable cells remaining following SAA treatment. 
SAA of various concentrations were used so as to allow for the 
detection of dose-dependent effect, if any. The use of various 
concentrations would also allow us to determine the concentration of 
SAA to be used for further studies. 
Cells were treated with either FBS free DMEM or 5, 10, 20, 40 or 
80μg/ml of SAA for 24 h. The presence of a dose-dependent effect as 
observed from Figure 12 shows that SAA has a negative effect on cell 
viability. However, the effect of SAA on RAW264.7 viability was 
found to be negligible when cells were treated with 5-20μg/ml of SAA. 
Effect of SAA on viability of RAW264.7 was only found to be 
significant when cells were treated with 40μg/ml and 80μg/ml of SAA. 
With these observations, subsequent experiments were carried out 
using 40μg/ml and 80μg/ml of SAA.  
From the MTT assay, we are able to conclude that at low 
concentrations, SAA has insignificant effect on the viability of 
RAW264.7. However, higher concentrations of SAA do have a 
significant negative effect on RAW264.7 viability.  
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Sytox and Hoechst double staining was carried out to detect for DNA 
fragmentation but results obtained were not significant.  
 
4.2.2. Effect of SAA on apoptotic gene targets 
A reduction in cell viability could be attributed to a few reasons, 
including cell death - due to necrosis, necroptosis or apoptosis; and cell 
cycle inhibition. In order to determine if negative effect of SAA on cell 
viability was due to apoptosis, quantitative real-time PCR was carried 
out to detect for regulation of apoptotic genes, if any.  
As observed in Figure 13, induction of Fas gene was observed 
following SAA treatment. Fas is one of the best characterized death 
receptor which plays an important role in the extrinsic death pathway. 
As previously mentioned, the binding of a FasL to Fas would activate 
the extrinsic pathway whereby FADD gets recruited, which in turn 
engages pro-caspase 8 to form the DISC, eventually causing apoptosis. 
The up-regulation of Fas gene by more than 10 fold at 3 h following 
SAA treatment as observed in Figure 13 would mean a higher chance 
of interaction between Fas and FasL and therefore, a greater 
probability of apoptosis occurring following SAA treatment.  
Other than Fas, Bcl-2 was also found to be significantly regulated 
following SAA treatment. However, in contrast to Fas, Bcl-2 gene was 
found to be down-regulated (Figure 14). Located on the mitochondria 
membrane, Bcl-2 is known for its anti-apoptotic properties in the 
intrinsic apoptotic pathway. Bcl-2 inhibits apoptosis by inhibiting the 
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opening of mitochondria membrane pores thus, preventing the release 
of mitochondrial pro-apoptotic proteins into the cytosol. Cytochrome c, 
one of the pro-apoptotic molecules, when released into the cytosol, 
would associate with Apaf-1 and recruit pro-caspase 9, resulting in 
apoptosis eventually. The down-regulation of anti-apoptotic Bcl-2 gene 
by 1.6 fold following SAA treatment in this case, would favour the 
release of mitochondrial pro-apoptotic molecule and thus, promote 
apoptosis via the intrinsic pathway.  
As can be seen from Figure 14, significant down-regulation of Bcl-2 
was observed only at 3 h and 24 h. We are unable to account for the 
lack of effect at 6 h.  
 
4.2.3. Effect of SAA on apoptotic protein targets 
As the executioner caspase, caspase 3 would be cleaved by upstream 
caspase 8 and caspase 9 from the extrinsic and intrinsic apoptotic 
pathway respectively. Once cleaved, caspase 3 would be activated and 
could cleave downstream targets including CaD inhibitor. In the 
absence of the inhibitor, CaD enters into the nucleus to degrade DNA, 
a hallmark of apoptosis. The level of caspase 3 thus, provides an 
important indication of apoptosis occurring. With this, the protein level 
of caspase 3 was probed using western blot.  
From Figure 15, a reduction in the level of uncleaved caspase 3 could 
be seen with increasing time-point following SAA exposure. This 
would indicate an increase in the level of cleaved caspase 3, implying 
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the occurrence of apoptosis following SAA treatment. To date, 
minimal studies have been carried out to determine the ability of SAA 
to induce apoptosis.  Similar to what we have found, Jo and his team 
found SAA’s ability to induce the apoptosis of WISH cells (human 
amnion derived cells) through the activation of caspase 3 (Jo et al., 
2007). Another study carried out by Kho and his team reported 
apoptotic effect of SAA in HC11 mammary epithelial cells through the 
induction of caspase 3 (Kho et al., 2008).  From Figure 15, SAA is 
likely to have caused the apoptosis of RAW264.7 through caspase 3 
activation. 
PARP, a DNA repairing enzyme, is a downstream target of caspase 3. 
Caspase 3 when activated is able to cleave downstream PARP and thus, 
prevents DNA repair, facilitating apoptosis. The level of PARP protein 
would therefore, provide an indication of caspase 3 activation. Similar 
to caspase 3, protein level of PARP was investigated using western 
blot.  
From Figure 16, a reduction in the level of uncleaved PARP could be 
seen, indicating an increase in the level of cleaved PARP with 
increasing time-point following SAA exposure. This observation is 
consistent with what was observed for caspase 3 (Figure 15), further 
confirming the activation of caspase 3. The time-points investigated for 
PARP were longer compared to the time-points investigated for 
caspase 3 as PARP is found further downstream of caspase 3. As 
predicted, at 24 h, the longest time-point probed in this study, 
uncleaved PARP protein level was the lowest, indicating greater 
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apoptosis with increasing time-point. This result confirms the result of 
the MTT assay which was carried out using a 24 h time-point as well 
(Figure 12).  
With signs of apoptosis being detected at the downstream targets, the 
protein levels of caspases found upstream of caspase 3 were 
investigated with activation of these targets being expected. However, 
contrary to what we have expected, no changes were detected at the 
protein level of both uncleaved caspase 8 and caspase 9 following SAA 
treatment (Figure 17).  
A likely reason for the lack of both caspase 8 and caspase 9 activation 
following SAA treatment would be that these caspases were not 
involved in SAA-induced apoptosis in RAW264.7. SAA-induced 
apoptosis could have occurred independent of caspase 8 and caspase 9. 
Although uncommon, initiator caspase-independent apoptosis had been 
reported. For instance, granzyme B was reported to be responsible for 
the direct activation of caspase 3 by granule, even in the absence of 
initiator caspase activation (Barry et al., 2000). Carter and his team 
also reported their findings on an X-linked inhibitor of apoptosis 
(XIAP) inhibitor’s ability to activate caspase 3 even before caspase 8 
and caspase 9 were activated. Instead, it was found that caspase 3 was 
able to activate caspase 8 and caspase 9 which are found upstream of 
caspase 3 via a positive feedback loop (Carter et al., 2005).  An 
experiment done by Chen and her team found that Src inhibition would 
result in apoptosis, with caspase 3 activation being observed. However, 
similar to our situation, Chen and her team could not detect activation 
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of caspase 8 and caspase 9. The neutralization of FasL using an 
appropriate antibody also failed to prevent caspase 3 activation (Chen 
et al., 2005). As mentioned earlier, a study done by Jo and his team 
using WISH cells showed potential apoptotic ability of SAA (Jo et al., 
2007). Similar to our study, the team reported observation of caspase 3 
activation. However, they too, failed to mention activation of caspases 
found upstream of caspase 3. A possible reason for the lack of mention 
could be due to negative results obtained when assays were carried out 
to look out for activation of upstream caspases. It is therefore, possible 
that SAA-induced apoptosis occurred independent of caspase 8 and 
caspase 9.  
These results indicate that SAA has a negative effect on cell viability 
through apoptosis but the initiation is independent of caspase 8 and 
caspase 9.  
 
4.2.4. Role of NFκB in SAA-induced apoptosis 
Earlier, we found that SAA is able to activate NFκB through its effect 
on the degradation of IκB (Figure 5). As mentioned, NFκB is known 
for its cell survival mechanism through its control over various targets 
including cell death suppression genes (Morotti et al., 2006) and 
apoptotic genes (Lee et al., 2008). With the activation of NFκB by 
SAA, we thought that the apoptotic effect of SAA may have been 
suppressed and therefore, sought the use of NFκB inhibitor Bay11-
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7082 to see if a more pronounced effect of apoptosis could be induced 
by SAA when NFκB was inhibited.  
However, pretreatment of RAW264.7 with Bay11-7082 prior exposure 
to 80μg/ml of SAA resulted in the complete abolishment of the 
apoptotic effect of SAA (Figure 18). Unlike what was observed 
previously, where down-regulation of uncleaved caspase 3 and 
uncleaved PARP were detected (Figure 15 and Figure 16 respectively), 
no reduction could be detected in the protein level of uncleaved 
caspase 3 and PARP following SAA treatment when NFκB was 
inhibited. Like before, no lowering of uncleaved caspase 8 and caspase 
9 levels were observed following SAA treatment when NFκB was 
inhibted.  
From what we have observed in Figure 18, the inhibition of NFκB 
activity resulted in the elimination of apoptotic effect induced by SAA. 
This shows that instead of promoting cell survival, NFκB actually 
plays a role in SAA-induced apoptosis of RAW264.7. Although 
generally known for its role in promoting cell survival, NFκB has also 
been implicated in apoptosis. Studies have reported on the ability of 
NFκB to induce apoptosis, especially in cases when NFκB is 
excessively activated (Chopra et al., 2008). When pyrrolidine 
dithiocarbamate (PDTC) was used to block NFκB activity, Bessho and 
team observed that the apoptotic effect of etoposide on human 
hematopoietic cells HL-60 that was previously noted was completely 
abrogated. Similar to our findings, these results by Bessho and team 
suggested the importance of NFκB in etoposide-induced apoptosis of 
105 
 
HL60 (Bessho et al., 1994). Given the ability of NFκB to promote both 
cell survival and cell death, a consensus that both cell type and 
apoptotic stimuli would determine the ultimate outcome was reached 
(Chopra et al., 2008; Gozal et al., 2002; Zhu et al., 2001). In our case, 
NFκB was shown to play a role in SAA-induced cell death. The 
excessive activation of NFκB by SAA could be the cause of 
RAW264.7 apoptosis. 
The role of NFkB in inducing RAW264.7 apoptosis could not be 
shown via the MTT assay as pre-treatment of RAW264.7 with Bay11-
7082 alone killed majority of the cells by 24 h.  
 
4.2.5. Mechanism of SAA-induced apoptosis 
Despite knowing that NFκB plays a role in SAA-induced apoptosis of 
RAW264.7, the mechanism through which apoptosis occurred is still 
unclear. Furthermore, both caspase 8 and caspase 9 remained 
uncleaved following SAA treatment. (Figure 17). There is therefore, a 
need to gain more insight on the mechanism through which apoptosis 
occurred.  
It is known that apoptosis mainly occurs via 2 pathways, namely the 
extrinsic and the intrinsic pathway. We therefore, examined possible 
targets which might have played a role in regulating SAA-induced 
apoptosis via these two pathways. Research in recent years has proven 
the importance of JNK in both extrinsic and intrinsic apoptotic 
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pathway and thus, JNK level following SAA exposure was also 
investigated. 
 
4.2.5.1. Extrinsic apoptotic pathway 
4.2.5.1.1. Fas 
As mentioned, Fas was induced following SAA treatment 
(Figure 13) making it a likely candidate to have played a role in 
SAA-induced cell death under normal conditions. The lack of 
SAA-induced apoptosis when NFκB was inhibited (Figure 18) 
could be due to the reduction in Fas induction following NFκB 
inhibition. Therefore, Fas transcript level of Bay11-7082 
pretreated cells was probed following exposure to SAA. 
As can be seen from Figure 19, following incubation with 
80μg/ml of SAA, Bay11-7082 pretreated cells displayed 
significant suppression of Fas induction at both 1 h and 3 h as 
compared to cells which were not subjected to Bay11-7082 
pretreatment. At 6 h however, there was no significant 
difference in Fas expression with or without NFκB inhibtion 
following SAA exposure.  
The suppression of Fas induction at 1 h and 3 h following 
NFκB inhibition could be a reason for the lack of apoptosis in 
SAA-exposed Bay11-7082 pretreated cells, indicating that Fas 
could have played a role in SAA-induced apoptosis in the first 
place. The lack of significant changes in Fas expression at 6 h 
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with or without NFκB inhibition following SAA exposure, 
however, could not explain for the complete lack of apoptotic 
effect following NFκB inhibition with Bay11-7082. An 
explanation could be that caspases from Bay11-7082 pretreated 
RAW264.7 were probed only up to 6 h following SAA 
exposure. The effects of Fas induction, at 6 h following SAA 
treatment when NFκB was inhibited, on these targets might not 
be detectable within this short time-point as caspases are found 
further downstream of Fas. Exposure of Bay11-7082 pretreated 
RAW264.7 to SAA for a longer time-point may generate 
cleaved caspases, indicating the occurrence of apoptosis. 
Another explanation for the lack of caspase cleavage despite 
significant induction of Fas at 6 h when NFκB was inhibited 
would be that Fas does not play a role in SAA-induced 
apoptosis. Despite the up-regulation of Fas shown in Figure 13, 
this result shows that Fas is unlikely to play a role in the 
apoptosis of RAW264.7 following SAA treatment. SAA-
induced apoptosis observed when NFκB was not inhibited 
could have been caused by other players in the apoptotic 








A20 is one of the many downstream targets of NFκB. Attention 
was brought to this target as research in recent years has linked 
A20 with anti-apoptotic properties. Having shown the ability of 
SAA to induce NFκB (Figure 5), we next determined the effect 
of SAA on A20.  
As can be seen from Figure 20, cells treated with SAA 
displayed sharp and rapid induction of A20 gene expression 
within an hour. The dramatic elevation of A20 following SAA 
treatment was further confirmed by Figure 21 which showed 
corresponding A20 protein elevation in SAA-treated cells. 
As a downstream target of NFκB, the dramatic induction of 
A20 at shorter time-points likely reflects the activation of 
NFκB following SAA treatment. Feedback inhibitory effect of 
A20 on NFκB subsequently accounts for the reduction in A20 
induction at longer time-points. 
A20 is seen as anti-apoptotic as studies have shown the ability 
of A20 to inhibit both TNF- (Vereecke et al., 2009) and Fas-
induced apoptosis (Li et al., 2006). Investigations done by Won 
and team found the ability of A20 to prevent caspase 8 
activation thus, inhibiting apoptosis via the extrinsic pathway 
(Won et al., 2010). The up-regulation of A20 expression 
following SAA treatment (Figure 20 and Figure 21) could 
explain for the lack of caspase 8 activation (Figure 17). Given 
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the ability of A20 to inhibit caspase 8 activation, the drastic 
induction of A20 following SAA exposure would support the 
previous mention that Fas does not play a role in SAA-induced 
apoptosis since Fas-activated apoptosis would involve caspase 
8. TNFα, which was found to be induced by SAA as mentioned 
in the previous chapter (Figure 10), is also not likely to play a 
role in SAA-induced apoptosis. TNFα when bound to TNFR, 
would induce apoptosis following the activation of the caspase 
cascade. Like Fas, TNFα-induced apoptosis would involve 
caspase 8. As A20 is associated with inhibition of extrinsic 
apoptotic pathway, induction of A20 following SAA treatment 
would lead to the unlikelihood that the extrinsic pathway is 
involved in SAA-induced apoptosis in RAW264.7. 
When cells were pretreated with Bay11-7082 before being 
exposed to SAA, A20 induction was suppressed at both the 
transcript and protein level (Figure 22 and Figure 23 
respectively). This observation is in accordance to what we 
have expected since A20 is found downstream of NFκB. 
Despite inhibition of anti-apoptotic A20 following NFκB 
inhibition, apoptotic effect of SAA was abolished. Once again, 
this shows that the death-inducing effect of SAA observed 
when NFκB was not inhibited was regulated by other players 
and not be the extrinsic death receptors as more pronounced 
apoptotic effect would be expected following A20 suppression 
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if the extrinsic death receptors were responsible for the 
apoptotic effect. 
 
4.2.5.2. Intrinsic apoptotic pathway 
With the lack of favorable evidence to suggest that SAA-induced 
apoptosis occurred via the extrinsic pathway, we also examined 
targets of the intrinsic pathway to find out more on the cause of 
SAA-induced apoptosis. 
4.2.5.2.1. Bcl-2 
As mentioned, Bcl-2 gene expression was reduced when cells 
were exposed to both 40μg/ml and 80μg/ml of SAA for 3 h 
(Figure 14). This reduction in transcript level was confirmed by 
a similar reduction in Bcl-2 protein level following SAA 
treatment (Figure 24). As an anti-apoptotic protein, the down-
regulation of Bcl-2 would disrupt the pro-apoptotic and anti-
apoptotic molecule balance, thus favouring the cell to undergo 
apoptosis. 
As a downstream target of NFκB, Bcl-2 is usually induced 
following NFκB stimulation (Leibowitz and Yu, 2010; Kim, 
2005). In this case, however, NFκB appears to play a role in the 
down-regulation of Bcl-2 in RAW264.7 following SAA 
treatment. When RAW264.7 were pretreated with Bay11-7082, 
the reduction in Bcl-2 level following SAA treatment was 
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eliminated at both the transcript and protein level (Figure 25 
and Figure 26 respectively). A possible explanation for the role 
of NFκB in Bcl-2 reduction following SAA treatment could be 
that NFκB was over-stimulated by SAA. A study done by 
Cipollone and team also found that the down-regulation of Bcl-
2 in microalbuminuric diabetic patients was associated with 
enhanced NFκB expression (Cipollone et al., 2005). Another 
explanation could be that SAA induced, through NFκB, the 
regulation of a target which caused the down-regulation of Bcl-
2. The inhibition of NFκB following Bay11-7082 pretreatment 
prevented the regulation of the target by SAA and therefore, 
abolished the Bcl-2 reduction which was seen previously.  
The elimination of Bcl-2 reduction is consistent with the lack of 
caspase 3 and PARP cleavage when RAW264.7 were exposed 
to SAA with inhibition of NFκB. The elimination of Bcl-2 
reduction could thus, be a reason for the lack of apoptosis in 
Bay11-7082 pretreated RAW264.7 following SAA treatment. 
In other words, Bcl-2 is likely to play a role in SAA-induced 
apoptosis when NFκB was not inhibited. 
Following Bcl-2 reduction, cytochrome c could be released into 
the cytosol where it would kick-start the downstream caspase 
cascade. Despite reduction of Bcl-2 in SAA-treated RAW264.7 
under normal conditions, no caspase 9 activation was detected 
(Figure 17). Caspase 3, a downstream target of caspase 9, 
however, showed signs of activation with increasing time-
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points following SAA exposure (Figure 15). Caspase 3 was 
probably activated through a more direct mechanism (Chen et 
al., 2005). 
Other than cytochrome c, the down-regulation of Bcl-2 could 
also lead to the release of other pro-apoptotic molecules from 
the mitochondria. An example is IAP inhibitor, Smac/DIABLO 
(Sun et al., 2002). Survivin, a member of the IAP family, is an 
anti-apoptotic protein which promotes cell survival by binding 
to caspase 3 directly, preventing cleavage of caspase 3 (Tamm 
et al., 1998). The release of IAP inhibitor into the cytosol could 
inhibit Survivin, resulting in the direct activation of caspase 3 
to cause apoptosis, bypassing both caspase 8 and caspase 9 
activation. The release of IAP inhibitors following Bcl-2 
reduction would therefore, explain for caspase 3 activation 
despite absence of activation in upstream caspases as seen in 
this case. It is thus, possible that SAA induced apoptosis via the 
intrinsic pathway following the down-regulation of Bcl-2, 
though independent of caspase 9.  
 
4.2.5.3. JNK activation 
As a member of MAPK, JNK has been linked to apoptosis with 
prolonged activation of JNK thought to be required for both 
extrinsically and intrinsically-induced apoptosis (Dhanasekaran and 
Reddy, 2008; Lin, 2003). Specifically, JNK activation is found to 
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be important for TNFα-induced extrinsic cell death (Deng et al., 
2003; Lin, 2003). JNK activity is also found to be critical for the 
release of cytochrome c from mitochondria in intrinsic cell death 
(Dhanasekaran and Reddy, 2008). JNK activation could be 
inhibited by NFκB gene targets, including A20 (Kucharczak et al., 
2003). Activation of NFκB could thus, inhibit JNK activation, 
preventing apoptosis. This is one of the mechanisms through which 
NFκB promotes cell survival (Won et al., 2010). 
As shown in Figure 27, treatment of RAW264.7 with SAA did not 
induce the activation of JNK as can be seen from the absence of p-
JNK following SAA treatment. This result is expected as it 
confirms previous findings of NFκB activation (Figure 5) and A20 
stimulation (Figure 20 and Figure 21). The absence of p-JNK in 
this case could once again indicate that TNFα-induced apoptosis is 
not likely to have occurred following SAA exposure as some 
studies have shown that JNK activation is required for TNFα-
induced apoptosis to occur (Deng et al., 2003).  
Cytochrome c, when released into the cytosol, would interact with 
Apaf-1 to activate caspase 9. Given the importance of activated 
JNK in regulating the release of cytochrome c from the 
mitochondria into the cytosol, the absence of activated JNK 
following SAA treatment once again confirms our result that 
caspase 9 is not involved in SAA-induced apoptosis. Our analysis 
that probably other pro-apoptotic molecules and not cytochrome c 
was released from the mitochondria following Bcl-2 down-
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regulation after SAA treatment is also supported with this finding. 
The absence of persistent JNK activation following SAA treatment 
could be a reason for the lack of TNFα- and cytochrome c-induced 
apoptosis. 
The pretreatment of RAW264.7 with Bay11-7082 before they were 
incubated with 80μg/ml of SAA resulted in transient JNK 
activation as deduced by p-JNK detected at 5 min and 15 min 
following SAA exposure (Figure 28). Unlike persistent JNK 
activation, transient JNK activation is not associated with apoptosis 
(Lin, 2003). Instead, transient JNK activation is seen as a sign of 
cell survival (Dhanasekaran and Reddy, 2008). The transient JNK 
activation observed could explain for the lack of SAA-induced 
apoptosis when cells were pretreated with Bay11-7082 before 





















Atherosclerosis is a major cause of death in the world and both inflammation 
and apoptosis are known to contribute to different stages of this disease. As 
SAA is found to be elevated in atherosclerotic patients, the purpose of this 
study is to determine whether SAA could contribute to atherosclerosis via 
these two pathways. This chapter reviews the main findings of this study and 
provides suggestions for possible future work. 
 
5.1. SAA contributes to atherosclerosis through inflammation 
Atherosclerosis is an inflammatory disease. Our study has shown the ability of 
SAA to significantly induce ICAM-1 and MCP-1, both known to play 
important roles in the initiation of atherosclerosis; as well as MMP-9 and TF, 
both known for their roles in atherosclerotic progression, in RAW264.7 
macrophages. Given that induction of these targets by SAA was significantly 
suppressed when NFκB was inhibited, we conclude that SAA induced these 
four targets through NFκB. Furthermore, SAA was able to directly stimulate 
TNFα. The induction of both TNFα and NFκB following exposure to SAA 
could result in a prolonged inflammatory response. With the effect of SAA on 
the above mentioned inflammatory targets, we could conclude that SAA is 
able to contribute to atherosclerosis through the inflammatory pathway. The 






5.2. SAA contributes to atherosclerosis through apoptosis 
Apoptosis plays a key role in atherosclerotic progression through its negative 
effects on plaque stability. Via the MTT assay, the ability of SAA to reduce 
cell viability was first observed. Specific effect of SAA on apoptosis was later 
proven through the ability of SAA to regulate apoptotic target Bcl-2. 
Activation of caspase 3 and cleavage of PARP following SAA treatment 
further confirmed the ability of SAA to induce apoptosis of RAW264.7. 
Despite activation of downstream executioner caspase 3, activation of 
upstream initiator caspases could not be detected. The regulation of A20 and 
lack of JNK activation by SAA, too, showed the unlikelihood of the 
involvement of initiator caspases in SAA-induced apoptosis. Intrinsic cell 
death following Bcl-2 down-regulation is likely to have played a role in SAA-
induced apoptosis, though independent of caspase 9. Despite being known for 
its cell survival activity, inhibition of NFκB before SAA treatment abolished 
the apoptotic effect of SAA in RAW264.7, highlighting the importance of 
NFκB in SAA-induced apoptosis. With these results, we could conclude that 
SAA is likely to contribute to atherosclerosis through the apoptotic pathway. 
The summary findings are depicted in Figure 29. 
 
Overall, results obtained from this study suggest that SAA is not just a passive 
marker but an active mediator of atherosclerosis. It is able to actively 
contribute to atherosclerosis through both the inflammatory and apoptotic 
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5.3. Future work 
A limitation of this study is that SAA effect on inflammation and apoptosis 
was only carried out in murine macrophage cell line. In order to validate the 
relevance of the above findings, similar experiments could be repeated using 
primary cells such as murine bone marrow derived macrophages. Results 
obtained from this study indicated that SAA could induce apoptosis of 
RAW264.7. However, the detailed mechanism through which apoptosis 
occurred remains to be investigated. Through analysis, it is thought that the 
release of pro-apoptotic molecules, other than cytochrome c, from the 
mitochondria into the cytosol following SAA treatment played a role in SAA-
induced apoptosis. Further studies on pro-apoptotic proteins which could be 
released by the mitochondria during apoptosis would thus, be useful to 
confirm this analysis. Pro-apoptotic IAP inhibitor Smac/DIABLO is thought to 
be one likely candidate which could have induced the direct activation of 
caspase 3 following SAA treatment. However, more studies would have to be 
carried out to prove the involvement of Smac/DIABLO in SAA-induced 
apoptosis of RAW264.7.  
 
In this study, inflammatory and apoptotic effects of SAA were detected in 
RAW264.7 macrophages. However, it is unclear whether elevated SAA level 
in-vivo could induce similar effects in macrophages since physiological 
conditions are to a large extent, different from cell culture environment. As 
such, a similar study could be carried out using animal models of 
atherosclerosis. Recombinant SAA could be injected into mouse model of 
advanced stage atherosclerosis to see if changes in apoptotic macrophages 
120 
 
could be observed. Alternatively, transgenic mice which over-express SAA 
and are deficient in apolipoprotein E (apoE) could be fed a high fat diet to 
promote atherosclerotic lesion development. Comparing the amount of 
apoptotic macrophages detected in these mice with the amount of apoptotic 
macrophages detected in apoE deficient control mice after the animals were 
sacrificed would give us an indication of the role of SAA in promoting 
atherosclerosis through macrophage apoptosis.  
 
Other than investigating the effect of short-term exposure to SAA which was 
done in this study, the effect of long-term exposure to SAA should also be 
probed as it would be more physiologically realistic. Elevated levels of SAA 
are observed in diseases such as diabetes and obesity which are risk factors of 
atherosclerosis. The study on the effect of long term exposure to elevated 
levels of SAA may increase our knowledge on how these diseases increase the 
risk of atherosclerosis. Study on the chronic effects of SAA would not be 
feasible through a cell-culture model. Instead, the study on the role of SAA in 
atherosclerosis using animal models would allow us to determine the effects of 
SAA following chronic exposure. Data obtained through animal models would 
also be more meaningful and useful since it reflects both physiological and 
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